<SEC-DOCUMENT>0001140361-25-040671.txt : 20251106
<SEC-HEADER>0001140361-25-040671.hdr.sgml : 20251106
<ACCEPTANCE-DATETIME>20251106082215
ACCESSION NUMBER:		0001140361-25-040671
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20251106
DATE AS OF CHANGE:		20251106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Opus Genetics, Inc.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-276462
		FILM NUMBER:		251456311

	BUSINESS ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713
		BUSINESS PHONE:		248-681-9815

	MAIL ADDRESS:	
		STREET 1:		8 DAVIS DRIVE
		STREET 2:		SUITE 220
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Ocuphire Pharma, Inc.
		DATE OF NAME CHANGE:	20201109

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	REXAHN PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20050516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ny20058362x1_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<html><head>
    <title></title>
    <!-- Licensed to: Broadrdige Financial
         Document created using Broadridge PROfile 25.10.1.5333
         Copyright 1995 - 2025 Broadridge -->
  </head><body style="color: #000000;" bgcolor="#ffffff">
<!--Begin Page 1-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 456pt;"><a name="ny20058362x1_424b5_100-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 456pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">Filed Pursuant to Rule&#160;424(b)(5) <br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: right;">Registration No. 333-276462</div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 44.5pt; margin-left: 0pt; text-align: left;">Prospectus Supplement <br></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-left: 0pt; text-align: left;"><font style="font-weight: normal;">(To Prospectus dated January&#160;23, 2024) </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.25pt; text-align: center;"><img style="height: 77px; width: 190px;" src="logo_opusgenetics.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">3,827,751 Shares of Common Stock<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pre-Funded Warrants to Purchase 7,177,033 Shares of Common Stock<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">7,177,033 Shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrants </div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.25pt;"> </div></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are offering 3,827,751 shares of common stock, par value $0.0001 (the &#8220;common stock&#8221;), directly to several institutional investors pursuant to this prospectus supplement and the accompanying prospectus. The public offering price for each share of our common stock is $2.09. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are also offering 7,177,033 pre-funded warrants (each, a &#8220;Pre-Funded Warrant&#8221;) directly to certain of the purchasers who have elected to receive them in lieu of additional shares of our common stock. The public offering price for each such Pre-Funded Warrant is $2.0899, which is equal to the price per share at which the shares of common stock are sold in this offering, minus $0.0001, the exercise price of the Pre-Funded Warrants. The Pre-Funded Warrants offered hereby will be immediately exercisable and may be exercised at any time until exercised in full. This prospectus also relates to the offering of shares of common stock issuable upon exercise of the Pre-Funded Warrants. We collectively refer to the shares of common stock, Pre-Funded Warrants and the shares of common stock underlying the Pre-Funded Warrants as the &#8220;securities.&#8221; The Pre-Funded Warrants will be issued in certificate form. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;IRD&#8221;. On November&#160;5, 2025, the last reported sale price of our common stock was $2.12 per share. There is no established public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for listing of the Pre-Funded Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The common stock and Pre-Funded Warrants are being offered directly to the purchasers without a placement agent or underwriter. We are not paying underwriting discounts or commissions in connection with this offering. We have entered into a securities purchase agreement with the purchasers for the sale of all of the securities being offered hereunder. The gross proceeds to us before expenses will be approximately $23.0&#160;million. We estimate the total expenses of this offering will be approximately $0.3 million. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a &#8220;smaller reporting company&#8221; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company reporting requirements for this prospectus supplement and may elect to do so in future filings. See &#8220;<font style="font-style: italic;">Prospectus Supplement Summary&#8212;Implications of Being a Smaller Reporting Company</font>.&#8221; </div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.25pt;"> </div></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Investing in our securities involves a high degree of risk. Before making an investment decision, please read the information under &#8220;<u>Risk Factors</u>&#8221; beginning on page S-<a href="#sRF">6</a> of this prospectus supplement and under similar headings in any amendment or supplement to this prospectus supplement or the accompanying prospectus or in any filing with the Securities and Exchange Commission that is incorporated by reference herein.<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 459.81pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 276pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 53.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr class="BRDSX_header"><td style="width: 276pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">&#160;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.31pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pre-Funded<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Warrants </div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; border-bottom: none;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; border-bottom: 1pt solid #000000;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold; margin-top: 0pt; text-align: center;">Total </div></td></tr><tr><td style="width: 276pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Public offering price per share or Pre-Funded Warrant<font style="padding-left: 4.45pt;"></font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.31pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.78pt; text-align: left;">$<font style="padding-left: 31.5pt;">2.09</font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$<font style="padding-left: 27pt;">2.0899</font></div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 1.04pt; padding-bottom: 0.5pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt;">&#160;</div></td></tr><tr><td style="width: 276pt; padding-top: 0.17pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Proceeds to us, before expenses<font style="padding-left: 1.58pt;"></font></div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 53.31pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0.78pt; text-align: left;">$7,999,999.59</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$14,999,281.27</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 56.25pt; padding-top: 0.17pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$22,999,280.86</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 3pt; width: 276pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 53.31pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 3pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 3pt; width: 56.25pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The delivery of the shares of common stock and Pre-Funded Warrants to purchasers is expected to be made on or about November&#160;7, 2025, subject to the satisfaction of customary closing conditions. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 9pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS SUPPLEMENT AND THE ACCOMPANYING PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.<font style="font-weight: normal;"> </font></div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.25pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 62.5pt; text-align: center;">The date of this prospectus supplement is November&#160;5, 2025<font style="font-weight: normal;">.</font></div></div></div></div>
<!--End Page 1-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 2-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_101-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19.5pt; text-align: center;">Prospectus Supplement </div><a name="TOC"><!--Anchor--></a><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 432pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 18.89pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sATP">ABOUT THIS PROSPECTUS SUPPLEMENT<font style="padding-left: 1.56pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sATP"><font style="padding-left: 5pt;">S-1 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sPS">PROSPECTUS SUPPLEMENT SUMMARY<font style="padding-left: 0.26pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sPS"><font style="padding-left: 5pt;">S-2 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sTO">THE OFFERING<font style="padding-left: 2.85pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sTO"><font style="padding-left: 5pt;">S-4 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sRF"><font style="padding-left: 5pt;">S-6 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sFLS">FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.89pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sFLS"><font style="padding-left: 5pt;">S-8 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sUOP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sUOP"><font style="padding-left: 0.37pt;">S-11 </font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sDP">DIVIDEND POLICY<font style="padding-left: 1.2pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sDP">S-12 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sDIL">DILUTION<font style="padding-left: 1.74pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sDIL">S-13 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sDOS">DESCRIPTION OF SECURITIES WE ARE OFFERING<font style="padding-left: 4.73pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sDOS">S-14 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sPOD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sPOD">S-16 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sLM">S-17 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sEXP">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sEXP">S-17 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 3.84pt;"></font></a></div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sWYC">S-17 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#sIOC">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE<font style="padding-left: 3.01pt;"></font></a></div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 18.89pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: -0.01pt; text-align: left;"><a href="#sIOC">S-18</a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 432pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 8.56pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 18.89pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18.5pt; text-align: center;">Prospectus</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 432pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">ABOUT THIS PROSPECTUS <font style="padding-left: 1pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP"><font style="padding-left: 4.44pt;">ii</font> </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS">PROSPECTUS SUMMARY <font style="padding-left: 4.88pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS"><font style="padding-left: 5pt;">1</font> </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS <font style="padding-left: 0.99pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">7</font> </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS">FORWARD-LOOKING STATEMENTS <font style="padding-left: 2.56pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS"><font style="padding-left: 5pt;">8</font> </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUP">USE OF PROCEEDS <font style="padding-left: 1.74pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUP"><font style="padding-left: 0.37pt;">11</font> </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS">DESCRIPTION OF CAPITAL STOCK <font style="padding-left: 4.78pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS">12 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDBS">DESCRIPTION OF DEBT SECURITIES <font style="padding-left: 0.83pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDBS">16 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDW">DESCRIPTION OF WARRANTS <font style="padding-left: 1.94pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDW">22 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLOS">LEGAL OWNERSHIP OF SECURITIES <font style="padding-left: 1.4pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLOS">24 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPD">PLAN OF DISTRIBUTION <font style="padding-left: 0.65pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPD">27 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">LEGAL MATTERS <font style="padding-left: 4.89pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">30 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">EXPERTS <font style="padding-left: 3.44pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">30 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION <font style="padding-left: 0.51pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">30 </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tICI">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE <font style="padding-left: 4.68pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tICI">31</a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 432pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0.5pt; margin-left: 0pt; text-align: left;"> </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-i<br></div></div></div>
<!--End Page 2-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 3-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_102-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS SUPPLEMENT </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus supplement is part of a shelf registration statement on Form&#160;S-3 that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;). We provide information to you about this offering of securities in two separate documents that are bound together: (1) this prospectus supplement, which describes the specific details regarding this offering, and (2) the accompanying prospectus, which provides general information, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus,&#8221; we are referring to both documents combined. If the information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8201;&#8212;&#8201;for example, a document incorporated by reference in this prospectus supplement&#8201;&#8212;&#8201;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You should rely only on the information contained in, or incorporated by reference into, this prospectus supplement and in any free writing prospectus that we may authorize for use in connection with this offering. We have not authorized any other person to provide you with different or additional information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell or soliciting an offer to buy our securities in any jurisdiction in which an offer or solicitation is not authorized or in which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus supplement, and any free writing prospectus that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the section of this prospectus supplement entitled &#8220;<font style="font-style: italic;">Incorporation of Certain Information by Reference</font>&#8221; and in the section of the accompanying prospectus entitled &#8220;<font style="font-style: italic;">Where You Can Find More Information</font>.&#8221; </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of our common stock in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of our common stock and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In this prospectus supplement, the terms &#8220;Opus,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms refer to Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) and its subsidiaries, unless the context otherwise requires. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus supplement, the accompanying prospectus and the information incorporated herein or therein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference in this prospectus supplement are the property of their respective owners. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-1<br></div></div></div>
<!--End Page 3-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 4-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_103-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sPS"><!--Anchor--></a>PROSPECTUS SUPPLEMENT SUMMARY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This summary highlights information contained elsewhere in this prospectus supplement. Because it is a summary, it may not contain all of the information that is important to you. Accordingly, you are urged to carefully read the entire prospectus, any applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained in any applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement. You should also carefully read the information incorporated by reference into this prospectus supplement, including our financial statements, and the exhibits to the registration statement of which this prospectus supplement and the accompanying prospectus is a part.<font style="font-style: normal;"> </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Company Overview </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (&#8220;IRDs&#8221;) and other ophthalmologic disorders. Our headquarters is located in Durham, North Carolina. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">On October&#160;22, 2024, we acquired a private corporation then operating under the name &#8220;Opus Genetics Inc.&#8221; (&#8220;Private Opus&#8221;) pursuant to the terms of an Agreement and Plan of Merger, dated as of October&#160;22, 2024 (such agreement, the &#8220;Merger Agreement,&#8221; and the transaction consummated via the Merger Agreement, the &#8220;Opus Acquisition&#8221;). </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our pipeline includes assets from the adeno-associated virus (&#8220;AAV&#8221;) based gene therapy portfolio of Private Opus that address mutations in genes that cause different forms of Leber congenital amaurosis (&#8220;LCA&#8221;), bestrophinopathy, and retinitis pigmentosa. Our most advanced gene therapy program is designed to address mutations in the LCA5 gene (&#8220;LCA5&#8221;), which encodes the lebercilin protein. More specifically, we are developing OPGx-LCA5 to treat LCA5-associated IRD, an early-onset retinal degeneration, and an open-label, dose-escalation Phase 1/2 clinical trial is ongoing. OPGx-BEST1 is another gene therapy candidate in our portfolio. This asset is being developed for the treatment of IRDs associated with mutations in the BEST1 gene (&#8220;BEST1&#8221;), which can lead to legal blindness. Apart from gene therapies, our pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size as well as APX3330, a novel small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein) designed to slow the progression of non-proliferative diabetic retinopathy. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In November&#160;2022, we entered into a license and collaboration agreement (as amended, the &#8220;Viatris License Agreement&#8221;) with Viatris, Inc. (&#8220;Viatris&#8221;), pursuant to which we granted Viatris an exclusive license to develop, manufacture, import, export and commercialize our refractive product candidate Phentolamine Ophthalmic Solution 0.75% (&#8220;PS&#8221;). PS is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. PS was approved by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) for the treatment of pharmacologically induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents, or a combination thereof under the brand name RYZUMVI&#174; in September&#160;2023 and was launched commercially in April&#160;2024. Additionally, we are currently developing PS for decreased vision under mesopic (low) light conditions following keratorefractive surgery, pursuant to a received FDA agreement under Special Protocol Assessment for its LYNX-2, a Phase 3 clinical trial. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">Recent Developments </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company announced the successful completion of a Type B Regenerative Medicine Advanced Therapy (RMAT) meeting with the FDA regarding OPGx-LCA5, its gene therapy candidate for LCA caused by mutations in the LCA5 gene.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The meeting provided constructive feedback from the FDA on key elements of the Company&#8217;s registration strategy, including Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) and the pivotal trial design. The FDA acknowledged the significant unmet medical need for individuals with LCA5-related blindness and reaffirmed its commitment to regulatory flexibility for rare genetic diseases. To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated with OPGx-LCA5, all of whom have experienced clinically meaningful improvements in vision, providing evidence of biological activity with the potential for functional restoration of vision in individuals with advanced disease.</div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-2<br></div></div></div>
<!--End Page 4-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 5-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_103-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company will incorporate the FDA&#8217;s feedback into its updated clinical development and CMC plans for the Phase 3 portion of the study, which will include enrolling as few as eight participants in a single-arm, 12-month study utilizing an adaptive design and provides flexibility regarding endpoints and number of participants, reflective of LCA5 as a rare condition with an urgent medical need. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Company expects the Phase 3 portion of the trial will include a run-in period prior to dosing to evaluate the natural history of each participant to serve as their own control in the study. The Company is actively identifying patients for this segment and has enrolled the first participant. Efficacy and safety will be assessed using measures such as visual acuity, full-field stimulus testing, microperimetry, and Multi-Luminance Orientation and Mobility Test (MLoMT). Following availability of validated clinical drug supply manufactured with the intended commercial processes, dosing with OPGx-LCA5 is anticipated in the second half of 2026, with topline clinical data expected approximately one year later.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In September 2025, the FDA introduced the Rare Disease Evidence Principles (&#8220;RDEP&#8221;) review process to facilitate the approval of drugs intended to treat rare diseases with very small patient populations, a significant unmet medical need and a known genetic defect that is the major driver of the pathophysiology. With a patient population of fewer than 1,000 individuals, the Company believes that its LCA5 program meets the eligibility criteria for the RDEP process and plans to submit an application.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Including expected proceeds from this offering and based on current operating plans, the Company expects its cash resources will fund operations into the second half of 2027, excluding any potential proceeds from callable warrants or future milestone payments. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Implications of Being a Smaller Reporting Company </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which means that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&#160;million and our annual revenue was less than $100&#160;million during the most recently completed fiscal year. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements in our Annual Report on Form&#160;10-K, and smaller reporting companies have reduced disclosure obligations regarding executive compensation. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250&#160;million as of the end of that year&#8217;s second fiscal quarter and our annual revenue exceeds $100&#160;million during such completed fiscal year, or (ii) the market value of our common stock held by non-affiliates exceeds $700&#160;million, regardless of our annual revenue, as of the end of that year&#8217;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our consolidated financial statements with other public companies difficult or impossible. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Corporate Information </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our principal executive offices are located at 8 Davis Drive, Suite 220, Durham, NC 27713. Our telephone number is (248) 957-9024. Our website address is www.opusgtx.com. Additionally, our filings with the SEC are posted on our website at www.opusgtx.com. The information found on or accessible through our website is not part of this or any other report we file with or furnish to the SEC. The public can also obtain copies of these filings by accessing the SEC&#8217;s website at http://www.sec.gov.</div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-3<br></div></div></div>
<!--End Page 5-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 6-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_103-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sTO"><!--Anchor--></a>THE OFFERING </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">Common stock offered by us<font style="font-weight: normal; padding-left: 4.18pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">3,827,751 shares of common stock. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Pre-Funded Warrants offered by us<font style="font-weight: normal; padding-left: 3.98pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">7,177,033 Pre-Funded Warrants to certain of the purchasers who have elected to receive them in lieu of additional shares of our common stock. Each Pre-Funded Warrant will be immediately exercisable upon issuance at an exercise price of $0.0001 per share of our common stock and may be exercised at any time until exercised in full. This prospectus supplement also relates to the offering of the shares of common stock issuable upon exercise of these Pre-Funded Warrants. </div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 240pt; text-align: justify;">To better understand the terms of the Pre-Funded Warrants, you should carefully read the &#8220;<font style="font-style: italic;">Description of Securities We Are Offering</font>&#8221; section of this prospectus supplement. You should also read the provisions of the Pre-Funded Warrant, the form of which will be filed as an exhibit to a Current Report on Form&#160;8-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus forms a part. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common stock outstanding immediately before this offering<font style="font-weight: normal; padding-left: 0.74pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: left;">65,002,665 shares of common stock. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6pt; margin-left: 10pt; text-indent: -10pt; text-align: left;">Common stock to be outstanding immediately after this offering<font style="font-weight: normal; padding-left: 1.05pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">76,007,449 shares of common stock, assuming exercise in full of the Pre-Funded Warrants issued in this offering. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Use of proceeds <font style="font-weight: normal; padding-left: 4.05pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">We estimate that we will receive net proceeds of approximately $22.7 million from the sale of the securities offered by us in this offering, assuming full exercise of all Pre-Funded Warrants, and after deducting the estimated offering expenses payable by us. We intend to use the net proceeds from this offering to advance its LCA5 and BEST-1 gene therapy clinical programs, as well as for working capital and general corporate purposes. See &#8220;<font style="font-style: italic;">Use of Proceeds</font>&#8221; for additional information. </div><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">Nasdaq symbol<font style="font-weight: normal; padding-left: 3.4pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">Our common stock is listed on the Nasdaq Capital Market (the &#8220;Nasdaq&#8221;) under the symbol &#8220;IRD.&#8221; There is no established trading market for the Pre-Funded Warrants and we do not expect such markets to develop. In addition, we do not intend to apply for the listing of the Pre-Funded Warrants on any national securities exchange or other trading market. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-4<br></div></div></div>
<!--End Page 6-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 7-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_103-summary_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_sum1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; width: 216pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risk factors<font style="font-weight: normal; padding-left: 5.3pt;"></font></div><div class="BRDSX_sum2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: -12pt; margin-left: 240pt; text-align: justify;">An investment in our securities involves a high degree of risk. See &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; beginning on page S-<a href="#sRF">6</a> of this prospectus supplement and the other information included and incorporated by reference in this prospectus supplement for a discussion of the risk factors you should carefully consider before deciding to invest in our securities.</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The number of shares of common stock to be outstanding after the offering is based on 65,002,665 shares of common stock outstanding as of October&#160;31, 2025, and excludes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">28,254,518 shares of common stock issuable upon the exercise of warrants outstanding as of October&#160;31, 2025, with a weighted-average exercise price of $1.80 per share;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">8,832,895 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of October 31, 2025, with a weighted-average exercise price of $0.0001 per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">7,407,510 shares of common stock issuable upon the exercise of outstanding stock options outstanding as of October&#160;31, 2025 under our 2018 Equity Incentive Plan, 2020 Equity Incentive Plan and 2021 Inducement Plan; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">534,176 shares of common stock reserved for future issuance under our 2020 Equity Incentive Plan and 2021&#160;Inducement Plan outstanding as of October&#160;31, 2025; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">2,226,031 unvested restricted stock awards as of October&#160;31, 2025. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Unless expressly indicated or the context requires otherwise, all information in this prospectus supplement is as of October&#160;31, 2025 and assumes no exercise of outstanding stock options described above, no settlement of unvested restricted stock units described above, no exercise of any of the warrants or pre-funded warrants described above and exercise in full of the Pre-Funded Warrants issued in this offering. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-5<br></div></div></div>
<!--End Page 7-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 8-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_104-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sRF"><!--Anchor--></a>RISK FACTORS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">An investment in our securities involves a high degree of risk. Prior to making a decision about investing in our securities, prospective investors should consider carefully all of the information included and incorporated by reference or deemed to be incorporated by reference in this prospectus supplement and the accompanying prospectus, including the risk factors incorporated by reference herein from our Annual Report on Form&#160;10-K for the fiscal year ended <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125011410/ef20039022_10k.htm">December&#160;31, 2024</a> and our Quarterly Reports on Form&#160;10-Q for the quarterly period ended <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125019266/ef20047563_10q.htm">March&#160;31, 2025</a> and Form&#160;10-Q for the quarterly period ended <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125030836/ef20050389_10q.htm">June&#160;30, 2025</a>, as updated by annual, quarterly and other reports and documents we file with the SEC after the date of this prospectus supplement and that are incorporated by reference herein. Each of these risk factors could have a material adverse effect on our business, results of operations, financial position or cash flows, which may result in the loss of all or part of your investment. For more information, see &#8220;Where You Can Find More Information&#8221; and &#8220;Incorporation of Certain Information by Reference.&#8221;<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The risks described in these documents are not the only ones we face. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Further, past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. Please also read carefully the section below entitled &#8220;Forward-Looking Statements.&#8221; </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-align: left;">Risks Related to This Offering </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Management will have broad discretion as to the use of the proceeds from this offering, if any, and may not use the proceeds effectively. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We currently anticipate that any net proceeds from this offering will be used for general corporate purposes and working capital, including for preclinical studies and clinical trials and the advancement of our product candidates. However, we have not determined the specific allocation of the net proceeds from this offering, if any, among these potential uses. Our management will have broad discretion as to the application of the net proceeds from this offering, if any, and could use them for purposes other than those contemplated at the time of the offering. Our management may use the net proceeds for corporate purposes that may not improve our financial condition or market value. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including timely delivery of shares and indemnification for breach of contract. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If you purchase our common stock and Pre-Funded Warrants in this offering, you will incur immediate and substantial dilution in the book value of your shares. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The public offering price in this offering will be substantially higher than the net tangible book value per share of our common stock. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this offering will incur immediate dilution of $1.52 per share. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As a result of the dilution to investors purchasing securities in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will incur as a result of purchasing securities in this offering, see &#8220;Dilution.&#8221; </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 19.5pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Significant holders or beneficial holders of our common stock may not be permitted to exercise Pre-Funded Warrants that they hold. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Pre-Funded Warrants being offered hereby will prohibit a holder from exercising its Pre-Funded Warrants if doing so would result in such holder (together with such holder&#8217;s affiliates and any other persons acting as a group together with such holder or any of such holder&#8217;s affiliates) beneficially owning more than 4.99% of our common stock outstanding immediately after giving effect to the exercise, provided that, at the election of a holder and notice </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-6<br></div></div></div>
<!--End Page 8-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 9-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_104-risk_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">to us, such beneficial ownership limitation as to such holder shall be 9.99% of our common stock outstanding immediately after giving effect to the exercise. As a result, if you hold a significant amount of our securities, you may not be able to exercise your Pre-Funded Warrants for shares of our common stock, in whole or in part, at a time when it would be financially beneficial for you to do so. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">An investment in the Pre-Funded Warrants and our common stock has numerous tax consequences. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">There are numerous tax consequences to investors as a result of their investment in the Company. We encourage investors to seek advice from competent tax advisors as to the consequences of an investment in our Pre-Funded Warrants and common stock. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Future sales of a significant number of our shares of common stock in the public markets, or the perception that such sales could occur, could depress the market price of our shares of common stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Sales of a substantial number of our shares of common stock in the public markets, or the perception that such sales could occur, including from the exercise of outstanding warrants or sales of common stock issuable thereunder, could depress the market price of our shares of common stock and impair our ability to raise capital through the sale of additional equity securities. A substantial number of shares of common stock are being offered by this prospectus supplement. We cannot predict the number of these shares that might be sold nor the effect that future sales of our shares of common stock, including shares issuable upon the exercise of outstanding warrants, would have on the market price of our shares of common stock. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">There is no public market for the Pre-Funded Warrants being offered in this offering. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">There is no established public trading market for the Pre-Funded Warrants being offered in this offering, and we do not expect such markets to develop. In addition, we do not intend to apply to list the Pre-Funded Warrants on any securities exchange or nationally recognized trading system, including the Nasdaq. Without an active market, the liquidity of the Pre-Funded Warrants will be limited. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Holders of our Pre-Funded Warrants will have no rights as a common stockholder until they acquire our common stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Until holders of our Pre-Funded Warrants acquire shares of our common stock upon exercise of the Pre-Funded Warrants, the holders will have no rights with respect to shares of our common stock issuable upon exercise of the Pre-Funded Warrants. Upon exercise of the Pre-Funded Warrants, holders will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock. </div><div class="BRDSX_risk" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold; margin-top: 20.5pt; margin-left: 20pt; text-align: left;">You may experience future dilution as a result of future equity offerings. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share paid by any investor in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by any investor in this offering, and investors purchasing shares or other securities in the future could have rights superior to you. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by any investor in this offering. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-7<br></div></div></div>
<!--End Page 9-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 10-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_105-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sFLS"><!--Anchor--></a>FORWARD-LOOKING STATEMENTS</div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">This prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC that are incorporated by reference herein contain &#8220;forward-looking statements&#8221; within the meaning of the U.S.&#160;Private Securities Litigation Reform Act of 1995 and releases issued by the SEC and within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Exchange Act, which statements involve risks and uncertainties. All statements, other than statements of historical facts, contained in this prospectus supplement, the accompanying prospectus and the other documents we have filed with the SEC that are incorporated by reference herein, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, may be deemed to be forward-looking statements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Words such as, but not limited to, &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;suggest,&#8221; &#8220;strategy,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements included herein represent management&#8217;s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. You should not place undue reliance on forward looking statements. The cautionary statements set forth in this prospectus supplement, including in &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; and elsewhere, identify important factors which you should consider in evaluating our forward-looking statements. These factors include, among other things: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our clinical data related to gene therapies for the treatment of IRDs is preliminary and related to a relatively small group of patients, and, as a result, data that initially appears promising may be revised, updated or invalidated at a later data readout and/or may ultimately not be capable of duplication in additional patients; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Failure to successfully integrate our businesses following the Opus Acquisition could have a material adverse effect on our business, financial condition and results of operations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The Opus Acquisition significantly expanded our product pipeline and business operations and shifted our business strategies, which may not improve the value of our common stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our gene therapy product candidates are based on a novel technology that is difficult to develop and manufacture, which may result in delays and difficulties in obtaining regulatory approval; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our planned clinical trials may face substantial delays, result in failure, or provide inconclusive or adverse results that may not satisfy FDA requirements to further develop our therapeutic products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Delays or difficulties associated with patient enrollment in clinical trials may affect our ability to conduct and complete those clinical trials and obtain necessary regulatory approvals; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Changes in regulatory requirements could result in increased costs or delays in development timelines; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We depend heavily on the success of our product pipeline; if we fail to find strategic partners or fail to adequately develop or commercialize our pipeline products, our business will be materially harmed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop generic variants of our products even while our product patents remain active, thereby reducing our market share and potential revenue from product sales; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We do not currently have any sales or marketing infrastructure in place and we have limited drug research and discovery resources; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">The future commercial success of our products could significantly depend upon several uncertain factors, including third-party reimbursement practices and the existence of competitors with similar products; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Product liability lawsuits against us or our suppliers or manufacturers could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Failure to comply with health and safety laws and regulations could lead to material fines; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-8<br></div></div></div>
<!--End Page 10-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 11-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_105-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We have not generated significant revenue from sales of any products and expect to incur losses for the foreseeable future; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our future viability is difficult to assess due to our short operating history and our future need for substantial additional capital, access to which could be limited by any adverse developments that affect the financial services markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Raising additional capital may cause our stockholders to be diluted, among other adverse effects; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We operate in a highly regulated industry and face many challenges adapting to sudden changes in legislative reform or the regulatory environment, which affects our pipeline stability and could impair our ability to compete in international markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may not receive regulatory approval to market our developed product candidates within or outside of the U.S.; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">With respect to any of our product candidates that receive marketing approval, we may be subject to substantial penalties if we fail to comply with applicable regulatory requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our potential relationships with healthcare providers and third-party payors will be subject to certain healthcare laws and regulations, which could expose us to extensive potential liabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We rely on third parties for material aspects of our business, such as conducting our nonclinical and clinical trials and supplying and manufacturing bulk drug substances, which exposes us to certain risks; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may be unsuccessful in entering into or maintaining licensing arrangements (such as the Viatris License Agreement) or establishing strategic alliances on favorable terms, which could harm our business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our current focus on the cash-pay utilization for future sales of RYZUMVI may limit our ability to increase sales or achieve profitability with this product; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Inadequate patent protection for our product candidates may result in our competitors developing similar or identical products or technology, which would adversely affect our ability to successfully commercialize; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may be unable to obtain full protection for our intellectual property rights under U.S. or foreign laws; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We may become involved in lawsuits for a variety of reasons associated with our intellectual property rights, including alleged infringement suits initiated by third parties; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">As we grow, we may not be able to operate internationally or adequately develop and expand our sales, marketing, distribution, and other corporate functions, which could disrupt our operations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">The market price of our common stock is expected to be volatile; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Our common stock may be subject to delisting from the Nasdaq and delisting could adversely affect our ability to access capital markets; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Factors out of our control related to our securities, such as securities litigation or actions of activist stockholders, could adversely affect our business and stock price and cause us to incur significant expenses; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Instability and operational disruptions at government agencies, such as the FDA, may adversely impact our development and commercialization plans by causing delays and requiring the use of additional, unforeseen resources to obtain regulatory approval for trials and products in our pipeline; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Impact from current or proposed tariffs on imported goods we purchase; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">other risks and uncertainties, including those listed under the caption &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; in this prospectus supplement; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our expected use of proceeds from this offering. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Although we believe that we have a reasonable basis for each forward-looking statement contained in this prospectus supplement, the accompanying prospectus and the other documents we have filed with the SEC that are </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-9<br></div></div></div>
<!--End Page 11-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 12-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_105-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: justify;">incorporated by reference herein, we caution you that these statements are based on our projections of the future that are subject to known and unknown risks and uncertainties and other factors that may cause our actual results, level of activity, performance or achievements expressed or implied by these forward-looking statements, to differ. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements should be regarded solely as our current plans, estimates and beliefs. We have included important factors in the cautionary statements included in this prospectus supplement, the accompanying prospectus, and the other documents we have filed with the SEC that are incorporated by reference herein, particularly in the section entitled &#8220;<font style="font-style: italic;">Risk Factors</font>&#8221; of this prospectus supplement, which we believe could cause our actual results to be materially different from the plans, intentions and expectations disclosed in the forward-looking statements we make. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Any forward-looking statement speaks only as of the date on which that statement is made. We assume no obligation to update any forward-looking statements to reflect events or circumstances after the date of this prospectus supplement, except as may otherwise be required by the federal securities laws. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You should read this prospectus supplement, the accompanying prospectus, documents we have filed with the SEC that are incorporated by reference herein and therein and any free writing prospectus we provide you completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-10<br></div></div></div>
<!--End Page 12-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 13-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_106-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sUOP"><!--Anchor--></a>USE OF PROCEEDS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We estimate that we will receive net proceeds of approximately $22.7 million from the sale of the securities offered by us in this offering, assuming exercise in full of the Pre-Funded Warrants, and after deducting the estimated offering expenses payable by us. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We intend to use the net proceeds from this offering to advance its LCA5 and BEST-1 gene therapy clinical programs, as well as for working capital and general corporate purposes. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus supplement, we cannot currently allocate specific percentages of the net proceeds that we may use for the purposes specified above, and we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our actual use of net proceeds may vary significantly depending on numerous factors, including the progress of our development efforts, the timing and costs associated with the manufacture and supply of any of our product candidates and any unforeseen cash needs. As a result, our management will have broad discretion over the use of the net proceeds from this offering. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We may temporarily invest the net proceeds in a variety of capital preservation instruments, including investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government, or may hold such proceeds as cash until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically for such purposes. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-11<br></div></div></div>
<!--End Page 13-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 14-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_106-use_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sDP"><!--Anchor--></a>DIVIDEND POLICY </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We have never declared nor paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to declare cash dividends will be made at the discretion of our board of directors (the &#8220;Board&#8221;), subject to compliance with applicable laws and covenants under current or future credit facilities, which may restrict or limit our ability to pay dividends, and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that the Board may deem relevant. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-12<br></div></div></div>
<!--End Page 14-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 15-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_106-use_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sDIL"><!--Anchor--></a>DILUTION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">If you invest in our common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per share of our common stock and the net tangible book value per share of our common stock upon consummation of this offering. Dilution results from the fact that the public offering price is substantially in excess of the book value per share attributable to the existing stockholders for the presently outstanding stock. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The historical net tangible book value of our common stock, as of June&#160;30, 2025, was approximately $17.5&#160;million, or approximately $0.29 per share of common stock. Historical net tangible book value (deficit) per share is determined by dividing the number of outstanding shares of common stock into its total tangible assets (total assets less intangible assets) less total liabilities and preferred shares, if any. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Investors purchasing securities in this offering will incur immediate and substantial dilution. After giving effect to the sale of (i) shares of our common stock in this offering at the public offering price of $2.09 per share of common stock and (ii) Pre-Funded Warrants in this offering at the public offering price of $2.0899 per Pre-Funded Warrant, and after deducting estimated offering costs payable by us, our as adjusted net tangible book value as of June&#160;30, 2025 would have been approximately $40.2 million, or approximately $0.57 per share of common stock. This represents an immediate increase in net tangible book value of $0.28 per share to existing stockholders, and an immediate dilution in the as adjusted net tangible book value of $1.52 per share to investors purchasing shares of our common stock in this offering. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-indent: 20pt; text-align: left;">The following table illustrates this per share dilution: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;"> </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 384pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 22.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 22.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 384pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Public offering price per share of common stock<font style="padding-left: 2.32pt;"></font></div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$2.09 </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 10pt; text-align: left;">Historical net tangible book value per share as of June&#160;30, 2025<font style="padding-left: 3pt;"></font></div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$0.29</div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 20pt; text-indent: -10pt; text-align: left;">Increase/decrease in as adjusted net tangible book value per share attributable to this offering<font style="padding-left: 3.72pt;"></font></div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$0.28</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">As adjusted net tangible book value as of June&#160;30, 2025 after giving effect to this offering<font style="padding-left: 4.52pt;"></font></div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$0.57 </div></td></tr><tr><td style="width: 384pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">Dilution per share to investors<font style="padding-left: 2.11pt;"></font></div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 22.5pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">$1.52</div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 384pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 22.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 9.75pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 22.5pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The discussion and table above assumes exercise in full of the Pre-Funded Warrants and are based on 59,908,055 shares of common stock outstanding as of June&#160;30, 2025 and excludes: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">29,433,401 shares of common stock issuable upon the exercise of warrants outstanding as of June&#160;30, 2025, with a weighted-average exercise price of $1.91 per share;</div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">8,832,895 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of June 30, 2025, with a weighted-average exercise price of $0.0001 per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">6,654,935 shares of common stock issuable upon the exercise of outstanding stock options outstanding as of June&#160;30, 2025 under our 2018 Equity Incentive Plan, 2020 Equity Incentive Plan and 2021 Inducement Plan; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">836,920 shares of common stock reserved for future issuance under our 2020 Equity Incentive Plan and 2021&#160;Inducement Plan outstanding as of June&#160;30, 2025; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">2,235,269 unvested restricted stock awards as of June&#160;30, 2025. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">To the extent that outstanding stock options, warrants and/or pre-funded warrants are exercised, new stock options are issued, restricted stock units are settled or we issue additional shares of common stock in the future, there will be further dilution to investors purchasing shares of common stock in this offering. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-13<br></div></div></div>
<!--End Page 15-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 16-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_107-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sDOS"><!--Anchor--></a>DESCRIPTION OF SECURITIES WE ARE OFFERING </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The following is a summary of the material terms and provisions of the common stock and the Pre-Funded Warrants that are being offered hereby. This summary is subject to, and qualified in its entirety by, the provisions of the Pre-Funded Warrant, the form of which will be filed as an exhibit to a Current Report on Form&#160;8-K in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus forms a part. Prospective investors should carefully review the terms and provisions set forth in the form of Pre-Funded Warrant.<font style="font-style: normal;"> </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are offering 3,827,751 shares of common stock and 7,177,033 Pre-Funded Warrants to purchase shares of common stock. The shares of our common stock issuable from time to time upon exercise of the Pre-Funded Warrants, if any, are also being offered pursuant to this prospectus supplement and the accompanying prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12.5pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">As of the date of this prospectus supplement, our certificate of incorporation authorizes us to issue up to 135,000,000 shares of capital stock, all with a par value of $0.0001 per share, of which: 125,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock (&#8220;preferred stock&#8221;). As of October&#160;31, 2025, 65,002,665 shares of common stock were outstanding. All outstanding shares of common stock are duly authorized, validly issued, fully paid, and nonassessable. All authorized but unissued shares of our common stock are available for issuance by the Board without any further stockholder action, except as required by the listing standards of Nasdaq. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Voting Rights. <font style="font-style: normal;">Generally, holders of our common stock are entitled to cast one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Except as may be provided in the certificate of incorporation or by the Board, holders of common stock have the exclusive right to vote for the election of directors and for all other purposes. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Dividend Rights.<font style="font-style: normal;"> Holders of our common stock have equitable rights to receive dividends, as may be lawfully declared from time to time by the Board, subject to any preferential rights of holders of any outstanding shares of preferred stock. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Liquidation.<font style="font-style: normal;"> In the event of our liquidation, dissolution, or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then-outstanding. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Rights and Preferences.<font style="font-style: normal;"> Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences, and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </font></div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Pre-Funded Warrants </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The Pre-Funded Warrant will be issued in certificate form. The term &#8220;pre-funded&#8221; refers to the fact that the purchase price of our common stock in this offering includes almost the entire exercise price that will be paid under the Pre-Funded Warrants, except for a nominal remaining exercise price of $0.0001. The purpose of the Pre-Funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, upon election of the holder, 9.99%) of our outstanding common stock following the consummation of this offering the opportunity to make an investment in the Company without triggering their ownership restrictions, by receiving Pre-Funded Warrants in lieu of our common stock which would result in such ownership of more than 4.99% (or 9.99%), and receive the ability to exercise their option to purchase the shares underlying the Pre-Funded Warrants at such nominal price at a later date. The holder of a Pre-Funded Warrant will not be deemed a holder of our underlying common stock until the Pre-Funded Warrant is exercised. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Duration and Exercise Price. <font style="font-style: normal;">The Pre-Funded Warrants offered hereby will have an exercise price of $0.0001&#160;per share. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. The exercise prices and numbers of shares of common stock issuable upon exercise are subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-14<br></div></div></div>
<!--End Page 16-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 17-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_107-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Exercise Limitation<font style="font-style: normal;">. A holder (together with its affiliates) may not exercise any portion of such holder&#8217;s Pre-Funded Warrants to the extent that the holder would own more than 4.99% (or, upon the election of the holder prior to the issuance of any Pre-Funded Warrants, 9.99%) of the common stock then outstanding after giving effect to such exercise. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Transferability. <font style="font-style: normal;">Subject to applicable laws, a Pre-Funded Warrant may be transferred at the option of the holder upon surrender of the Pre-Funded Warrant to us together with the appropriate instruments of transfer. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Fractional Shares. <font style="font-style: normal;">No fractional shares or scrip representing fractional shares of common stock will be issued upon the exercise of the Pre-Funded Warrants. Rather, the number of shares of common stock to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Trading Market. <font style="font-style: normal;">There is no established trading market for any of the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Pre-Funded Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Pre-Funded Warrants will be limited. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Rights as a Shareholder<font style="font-style: normal;">. Except as otherwise provided in the Pre-Funded Warrants or by virtue of the holders&#8217; ownership of shares of our common stock, the holders of Pre-Funded Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until such Pre-Funded Warrant holders exercise their Pre-Funded Warrants. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Fundamental Transaction. <font style="font-style: normal;">In the event of a fundamental transaction, as described in the Pre-Funded Warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the Pre-Funded Warrants will be entitled to receive upon exercise of the Pre-Funded Warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Pre-Funded Warrants immediately prior to such fundamental transaction. </font></div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Waivers and Amendments.<font style="font-style: normal;"> No term of the Pre-Funded Warrants may be amended or waived without the written consent of the holder of such Pre-Funded Warrant. </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-15<br></div></div></div>
<!--End Page 17-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 18-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_108-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sPOD"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">We are selling 3,827,751 shares of our common stock and 7,177,033 Pre-Funded Warrants to purchase shares of our common stock at a public offering price of $2.09 per share of common stock (and $2.0899 per Pre-Funded Warrant) under this prospectus supplement directly to certain purchasers, without a placement agent, underwriter, broker or dealer. The closing of this offering is subject to customary closing conditions. We expect that the sale of the shares of our common stock and Pre-Funded Warrants will be completed on or around the date indicated on the cover page of this prospectus supplement. The shares of common stock and Pre-Funded Warrants will be issued separately. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The shares of common stock and Pre-Funded Warrants offered by this prospectus supplement will be sold pursuant to a securities purchase agreement between us and the purchasers purchasing shares of our common stock and Pre-Funded Warrants in this offering. For the complete terms of the securities purchase agreement, you should refer to the form of securities purchase agreement which will be filed as an exhibit to the Current Report on Form&#160;8-K to be filed with the SEC in connection with this offering, and which is incorporated by reference into the registration statement of which this prospectus supplement and the accompanying prospectus is part. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">The transfer agent for our common stock is Equiniti Trust Company, LLC. The transfer agent and registrar&#8217;s address is 55 Challenger Road, Floor 2, Ridgefield Park, NJ 07660. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: justify;">Our common stock is currently listed on the Nasdaq under the symbol &#8220;IRD.&#8221; On November&#160;5, 2025, the closing price of our common stock was $2.12 per share. The Pre-Funded Warrants are not listed for trading on any securities exchange. There is no established public trading market for the Pre-Funded Warrants, and we do not expect a market to develop. We do not intend to list the Pre-Funded Warrants on the Nasdaq or any other national securities exchange or nationally recognized trading system. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-16<br></div></div></div>
<!--End Page 18-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 19-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_109-legal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sLM"><!--Anchor--></a>LEGAL MATTERS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">Sidley Austin LLP will pass upon the validity of the securities offered by this prospectus supplement and the accompanying prospectus. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="sEXP"><!--Anchor--></a>EXPERTS </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The consolidated financial statements of Opus Genetics, Inc. appearing in Opus Genetics, Inc.&#8217;s Annual Report (Form&#160;10-K) for the year ended <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125011410/ef20039022_10k.htm">December&#160;31, 2024</a>, have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. The financial statements of Private Opus appearing in Opus Genetics, Inc.&#8217;s Current Report on Form&#160;8-K/A dated <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036125000467/ef20041180_8ka.htm">January&#160;7, 2025</a> have been audited by Ernst &amp; Young LLP, as set forth in their report included therein and incorporated herein by reference. Such financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="sWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are a reporting company and file annual, quarterly and current reports, proxy statements and other information with the SEC. We have filed with the SEC a registration statement under the Securities Act with respect to the securities being offered under this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities being offered under this prospectus supplement and the accompanying prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. You may obtain copies of the registration statement and its exhibits via the SEC&#8217;s website at http://www.sec.gov. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We are subject to the informational and reporting requirements of the Exchange Act and have filed and will file annual, quarterly and current reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available for inspection and copying at the SEC&#8217;s public reference facilities and on the SEC&#8217;s website referred to above. We maintain a website at www.opusgtx.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not part of this prospectus supplement and the inclusion of our website address in this prospectus supplement is an inactive textual reference only.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-17<br></div></div></div>
<!--End Page 19-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 20-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_110-incorp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="sIOC"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">The SEC allows us to &#8220;incorporate by reference&#8221; information into this prospectus supplement. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be a part of this prospectus supplement, except for any information that is superseded by other information that is included in this prospectus supplement. The information we incorporate by reference is an important part of this prospectus supplement and information that we subsequently file with the SEC will automatically update and supersede information in this prospectus supplement and in our other filings with the SEC. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We incorporate by reference the documents listed below, which we have already filed with the SEC, and any filings we make with the SEC under Section&#160;13(a), 13(c), 14 or 15(d) of the Exchange Act (1) on or after the date of filing of the registration statement of which this prospectus supplement and the accompanying prospectus forms a part and (2) on or after the date of this prospectus until the earlier of the date on which all of the securities registered hereunder have been sold or the registration statement of which this prospectus supplement and the accompanying prospectus is a part has been withdrawn (in each case, other than information that is deemed, under SEC rules, not to have been filed): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2024, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125011410/ef20039022_10k.htm">March&#160;31, 2025</a> (the &#8220;2024 Annual Report&#8221;); </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">our Quarterly Reports on Form&#160;10-Q for the fiscal quarters ended March&#160;31, 2025, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125019266/ef20047563_10q.htm">May&#160;15, 2025</a> and Form&#160;10-Q for the fiscal quarter ended June&#160;30, 2025, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125030836/ef20050389_10q.htm">August&#160;13, 2025</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the information contained in our Definitive Proxy Statement on Schedule 14A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000199937125003703/opus-defc14a_043025.htm">April&#160;2, 2025</a>, that is incorporated by reference in the 2024 Annual Report; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">Current Reports on Form&#160;8-K and Form&#160;8-K/A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125000467/ef20041180_8ka.htm">January&#160;7, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125001013/ny20040461x2_8k.htm">January&#160;14, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125001819/ef20041877_8k.htm">January&#160;23, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125001899/ef20042243_8k.htm">January&#160;24, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125006961/ef20044862_8k.htm">March&#160;4, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000199937125002866/ird-8k_031925.htm">March&#160;20, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125010064/ef20045985_8k.htm">March&#160;24, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125012366/ef20046946_8k.htm">April&#160;4, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125016948/ef20048353_8k.htm">May&#160;1, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125023172/ef20050845_8k.htm">June&#160;20, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125023648/ef20051087_8k.htm">June&#160;25, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125023732/ef20051231_8k.htm">June&#160;26, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125026853/ef20052404_8k.htm">July&#160;23, 2025</a> (excluding Item&#160;7.01 and the related exhibits), <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125032533/ef20054479_8k.htm">August&#160;25, 2025</a>, <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125033668/ef20054946_8k.htm">September&#160;2, 2025</a> (excluding Item&#160;7.01 and the related exhibit) and <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125036637/ef20056246_8k.htm">September&#160;30, 2025</a> (excluding Item&#160;7.01 and the related exhibits); and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: justify;">the description of our common stock contained in our Registration Statement on Form&#160;8-A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036119010684/form8a12b.htm">June&#160;7, 2019</a>, as updated by <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036125011410/ef20039022_ex4-12.htm">Exhibit&#160;4.12</a> to the 2024 Annual Report and any other amendment or report filed for the purpose of updating such description. </div></td></tr></table><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">We also incorporate by reference any future filings (other than current reports furnished under Item&#160;2.02 or Item&#160;7.01 of Form&#160;8-K and exhibits filed on such form that are related to such items unless such Form&#160;8-K expressly provides to the contrary) made with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, including those made after the date of the initial filing of the registration statement of which this prospectus supplement and the accompanying prospectus is a part and those made after the effectiveness of such registration statement, until the termination of the offering of the common stock made by this prospectus supplement, and such filings will become a part of this prospectus supplement from the respective dates that such documents are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus supplement. Any statements in any such future filings will automatically be deemed to modify and supersede any information herein or in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier statements. </div><div class="BRDSX_para" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-indent: 20pt; text-align: justify;">You may request and obtain a copy of any of the filings incorporated herein by reference, at no cost, by writing or telephoning us at the following address or phone number: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Opus Genetics, Inc.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">8 Davis Drive, Suite 220<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Durham, NC 27709<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(248) 957-9024<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attn: Dr.&#160;George Magrath, Chief Executive Officer </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">S-18<br></div></div></div>
<!--End Page 20-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 21-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 456pt;"><a name="ny20058362x1_424b5_200-cov_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 456pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">PROSPECTUS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 14.25pt; text-align: center;"><img style="height: 96px; width: 335px;" src="logo_ocuphire.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 20.5pt; text-align: center;">$175,000,000<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">&#8195; <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Common Stock <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Preferred Stock <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Debt Securities <br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 14pt; font-weight: bold; margin-top: 0pt; text-align: center;">Warrants </div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 13.25pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may, from time to time, offer and sell up to $175,000,000 of any combination of the securities described in this prospectus, either individually or in combination, at prices and on terms described in one or more supplements to this prospectus. We may also offer common stock or preferred stock upon conversion of debt securities, or common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon exercise of warrants. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus describes some of the general terms that may apply to an offering of our securities. We will provide the specific terms of these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as the documents incorporated by reference, before buying any of the securities being offered. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement.<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will sell these securities directly to investors, through agents designated from time to time or to or through underwriters or dealers, on a continuous or delayed basis. For additional information on the methods of sale, you should refer to the section entitled &#8220;Plan of Distribution&#8221; in this prospectus on page <a href="#tPD">27</a> and in the applicable prospectus supplement. If any underwriters are involved in the sale of any securities with respect to which this prospectus is being delivered, the names of such underwriters and any applicable discounts or commissions and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we expect to receive from such sale will also be set forth in a prospectus supplement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;OCUP.&#8221; On January&#160;9, 2024, the last reported sale price of our common stock on the Nasdaq Capital Market was $3.25 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the Nasdaq Capital Market or other securities exchange of the securities covered by the prospectus supplement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; contained in this prospectus on page <a href="#tRF">7</a>, in our most recent Annual Report on Form&#160;10-K and Quarterly Report on Form&#160;10-Q incorporated by reference into this prospectus, in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the other documents that are incorporated by reference into this prospectus.<font style="font-weight: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6pt; margin-left: 0pt; text-align: left;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</div><div><div class="BRDSX_rule-partial" style="height: 0pt; width: 96pt; border-bottom: 1pt solid #000000; margin-bottom: 2pt; margin-left: auto; margin-right: auto; margin-top: 14.75pt;"> </div></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 8pt; text-align: center;">The date of this prospectus is January 23, 2024.</div></div></div></div>
<!--End Page 21-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 22-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_201-toc_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;">TABLE OF CONTENTS </div><table cellspacing="0" cellpadding="0" class="BRDSX_fintab" style="margin-top: 4pt; width: 468pt; margin-left: auto; margin-right: auto;"><tr class="BRDSX_boxspacer"><td style="height: 6pt; width: 432pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 6pt; width: 10pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td></tr><tr><td style="width: 432pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP">ABOUT THIS PROSPECTUS<font style="padding-left: 4.33pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tATP"><font style="padding-left: 4.44pt;">ii</font> </a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS">PROSPECTUS SUMMARY<font style="padding-left: 2.84pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPS"><font style="padding-left: 5pt;">1</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF">RISK FACTORS<font style="padding-left: 4.32pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tRF"><font style="padding-left: 5pt;">7</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS">FORWARD-LOOKING STATEMENTS<font style="padding-left: 0.89pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tFLS"><font style="padding-left: 5pt;">8</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUP">USE OF PROCEEDS<font style="padding-left: 0.07pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tUP"><font style="padding-left: 0.37pt;">11</font></a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS">DESCRIPTION OF CAPITAL STOCK<font style="padding-left: 3.11pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDCS">12</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDBS">DESCRIPTION OF DEBT SECURITIES<font style="padding-left: 4.16pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDBS">16</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDW">DESCRIPTION OF WARRANTS<font style="padding-left: 0.27pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tDW">22</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLOS">LEGAL OWNERSHIP OF SECURITIES<font style="padding-left: 4.73pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLOS">24</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPD">PLAN OF DISTRIBUTION<font style="padding-left: 3.98pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tPD">27</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">LEGAL MATTERS<font style="padding-left: 3.22pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tLM">30</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">EXPERTS<font style="padding-left: 1.77pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tEXP">30</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">WHERE YOU CAN FIND MORE INFORMATION<font style="padding-left: 3.84pt;"></font></a></div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt; background-color: #CCEEFF;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; padding-bottom: 1.38pt; text-align: center; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tWYC">30</a></div></td></tr><tr><td style="width: 432pt; padding-top: 1.01pt; text-align: left; vertical-align: bottom;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tICI">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE<font style="padding-left: 3.01pt;"></font></a></div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="width: 10pt; padding-top: 1.01pt; text-align: center; vertical-align: bottom; white-space: nowrap;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;"><a href="#tICI">31</a></div></td></tr><tr class="BRDSX_boxspacer"><td style="height: 2.75pt; width: 432pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 13pt;"><div style="font-size: 1pt;">&#8194;</div></td><td style="height: 2.75pt; width: 10pt;"><div style="font-size: 1pt;">&#8194;</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">You should rely only on the information contained in, or incorporated by reference into, this prospectus and the applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different information. We are not making an offer to sell or seeking an offer to buy securities under this prospectus or the applicable prospectus supplement and any related free writing prospectus in any jurisdiction where the offer or sale is not permitted. The information contained in this prospectus, the applicable prospectus supplement or any related free writing prospectus, and the documents incorporated by reference herein and therein, are accurate only as of their respective dates, regardless of the time of delivery of this prospectus, the applicable prospectus supplement or any related free writing prospectus, or any sale of a security. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">i<br></div></div></div>
<!--End Page 22-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 23-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_202-about_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tATP"><!--Anchor--></a>ABOUT THIS PROSPECTUS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus is part of a registration statement on Form&#160;S-3 that we filed with the Securities and Exchange Commission, or SEC, using a &#8220;shelf&#8221; registration process under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf registration statement, we may sell from time to time in one or more offerings up to a total dollar amount of $175,000,000 of common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination with other securities as described in this prospectus. This prospectus provides you with a general description of the securities we may offer. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each time we sell any type or series of securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. We may also add, update or change in a prospectus supplement or free writing prospectus any of the information contained in this prospectus or in the documents we have incorporated by reference into this prospectus. This prospectus, together with the applicable prospectus supplement, any related free writing prospectus and the documents incorporated by reference into this prospectus and the applicable prospectus supplement, will include all material information relating to the applicable offering. You should carefully read both this prospectus and the applicable prospectus supplement and any related free writing prospectus, together with the additional information described under &#8220;Where You Can Find More Information,&#8221; before buying any of the securities being&#160;offered. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Neither we, nor any agent, underwriter or dealer has authorized anyone to provide you with any information other than contained in, or incorporated by reference into, this prospectus and the applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should not assume that the information contained in or incorporated by reference in this prospectus or any prospectus supplement or in any such free writing prospectus is accurate as of any date other than their respective dates. Our business, financial condition, results of operations and prospects may have changed since those dates. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below under the section entitled &#8220;Where You Can Find More Information.&#8221; </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus to &#8220;Ocuphire,&#8221; &#8220;the company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar references refer to Ocuphire Pharma, Inc., a corporation under the laws of the State of Delaware. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus and the information incorporated herein by reference include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included or incorporated by reference into this prospectus, any applicable prospectus supplement or any related free writing prospectus are the property of their respective owners. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">ii<br></div></div></div>
<!--End Page 23-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 24-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_203-summary_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPS"><!--Anchor--></a>PROSPECTUS SUMMARY </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference herein and does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk&#160;Factors&#8221; contained in this prospectus, the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements and related notes, and the exhibits to the registration statement of which this prospectus is a part, before making your investment decision.<font style="font-style: normal;"> </font></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 19pt; text-align: center;">Ocuphire Pharma, Inc. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 18pt; margin-left: 0pt; text-align: left;">Overview </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are a clinical-stage ophthalmic biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 19pt; margin-left: 0pt; text-align: left;">APX3330 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our lead retinal product candidate, APX3330, is a first-in-class small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein). Ref-1 is a regulator of transcription factors such as HIF-1&#945; and NF-kB. Inhibiting REF-1 reduces levels of vascular endothelial growth factor (&#8220;VEGF&#8221;) and inflammatory cytokines which are known to play key roles in ocular angiogenesis and inflammation. Through inhibition of Ref-1, APX3330 normalizes the levels of VEGF to physiologic levels, unlike biologics that deplete VEGF below the levels required for normal function. APX3330 is an oral tablet administered twice per day for the treatment of diabetic retinopathy (&#8220;DR&#8221;). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">DR affects approximately 10&#160;million people with diabetes and is projected to impact over 14&#160;million Americans by 2050. DR is classified as Non-Proliferative Diabetic Retinopathy (&#8220;NPDR&#8221;), the early stage of the disease in which symptoms may be mild or nonexistent or Proliferative Diabetic Retinopathy (&#8220;PDR&#8221;) which is the more advanced stage of diabetic eye disease that can be highly symptomatic with loss of vision. Approximately 80% of the DR patients have NPDR that will progress to PDR if left untreated. Despite the risk for visual loss associated with this disease, over 90% of NPDR patients currently receive no course of treatment apart from observation by their eye care specialist until they develop sight-threatening complications. This is due to the treatment burden of the frequent eye injections required with currently approved therapies for this disease. APX3330 as an oral tablet has the potential to be an early, non-invasive treatment for the 8&#160;million NPDR patients in the US. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In January&#160;2023, we reported top-line efficacy and safety results from the ZETA-1 Phase 2 trial conducted in 103&#160;subjects (51 treated with 600 mg daily dose of APX3330) in DR, including moderately severe and severe NPDR and mild PDR, as well as patients with diabetic macular edema without loss of central vision. Although administration of APX3330 daily did not meet the study&#8217;s primary endpoint of percentage of patients with a &#8805; 2-step improvement in Early Treatment of Diabetic Retinopathy Study (&#8220;ETDRS&#8221;) diabetic retinopathy severity scale (&#8220;DRSS&#8221;) in the study eye at week 24 compared to placebo, efficacy was seen on the FDA agreed upon registration endpoint of &#8805;3-step worsening on a binocular DRSS Person Scale. Prevention or slowing of progression of DR to vision-threatening complication such as PDR is a clinically meaningful endpoint. APX3330 also demonstrated favorable safety and tolerability in diabetic patients. A successful End-of-Phase 2 (&#8220;EOP2&#8221;) meeting with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) was held in October&#160;2023 at which we obtained agreement on the Phase 3 registration endpoint supporting the advancement of APX3330 into Phase 3. Ocuphire plans to submit a Special Protocol Assessment (&#8220;SPA&#8221;) to agree on the clinical trial protocol and statistical analysis plan for the Phase 3 trials. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Prior to Ocuphire in-licensing the APX3330 product candidate, it had been studied by other sponsors in a total of 11 clinical trials (6 Phase 1 and 5 Phase 2) in a total of over 420 healthy volunteers or patients (with over 340&#160;APX3330-treated) for inflammatory (hepatic) and oncology indications, and had demonstrated evidence of target engagement, consistent pharmacokinetics, durability, and favorable safety and tolerability. Treatment-related </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">1<br></div></div></div>
<!--End Page 24-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 25-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_203-summary_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">adverse events were uncommon, and most were mild in severity. No clinically significant changes were observed in liver, kidney, or heart function. There were no treatment-related effects on hematologic or blood chemistry evaluations. APX3330 demonstrated favorable safety and tolerability in the ZETA-1 trial, consistent with the safety data from the prior 11 clinical trials. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We also in-licensed APX2009 and APX2014, which are second-generation analogs of APX3330. The unique mechanism of action of these Ref-1 inhibitors of reducing angiogenesis and inflammation could potentially be beneficial in treating other retinal diseases such as age-related macular degeneration (&#8220;AMD&#8221;), and geographic atrophy (&#8220;GA&#8221;). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are currently evaluating local delivery routes of APX3330 and its second-generation analogs in addition to the systemic (oral) route as part of its pipeline expansion in retinal therapies. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 13.5pt; margin-left: 0pt; text-align: left;">Phentolamine Ophthalmic Solution 0.75% (POS) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2022, we entered into a license and collaboration agreement (the &#8220;Nyxol License Agreement&#8221;) with FamyGen_Life Sciences, Inc. (acquired by Viatris, Inc. (&#8220;Viatris&#8221;) in January&#160;2023) pursuant to which we granted Viatris an exclusive license to develop, manufacture, import, export and commercialize our refractive product candidate Phentolamine Ophthalmic Solution 0.75%, formerly known as Nyxol (&#8220;POS&#8221;) for treating (a)&#160;reversal of pharmacologically-induced mydriasis, (b) night vision disturbances or dim light vision (&#8220;DLD&#8221;), and (c) presbyopia, and (ii) POS and low dose pilocarpine for treating presbyopia (together, the &#8220;Nyxol Products&#8221;) worldwide except for certain countries and jurisdictions in Asia (the &#8220;Viatris Territory&#8221;). </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the terms of the Nyxol License Agreement, Ocuphire in partnership with Viatris, will develop the Nyxol Products in the United States. Viatris agreed to reimburse us for budgeted costs related to the development of the Nyxol Products through each applicable FDA approval. Viatris is responsible for developing the Nyxol Products in countries and jurisdictions in the Viatris Territory outside of the United States. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">POS is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. POS can potentially be used across multiple indications such as treatment of pharmacologically-induced mydriasis (&#8220;RM&#8221;) (dilation of the pupil), presbyopia (age-related blurry near vision) and DLD (halos, glares and starbursts). Our management believes these multiple indications potentially represent a significant market opportunity. POS has been studied in a total of 12 clinical trials (3 Phase 1, 5 Phase 2 and 4&#160;Phase 3) in a total of over 1100 patients (with over 650 POS-treated) and has demonstrated promising clinical data across the three targeted refractive indications. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We submitted a new drug application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) in November&#160;2022 under the 505(b)(2) pathway for POS for RM; the FDA approved the NDA in September&#160;2023 under the brand name RYZUMVI&#8482;, which triggered a $10&#160;million milestone payment under the Nyxol License Agreement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We reported positive top-line data from multiple late-stage clinical trials for POS in RM, presbyopia and DLD. We reported positive top-line data from Phase 3 trials in RM: MIRA-2 in March&#160;2021, MIRA-3 in March&#160;2022 and MIRA-4 in April&#160;2022. We also reported positive top-line data from a Phase 2 trial of POS for treatment of presbyopia, both as monotherapy and with low-dose pilocarpine (pilocarpine hydrochloride ophthalmic solution&#160;0.4%, &#8220;LDP&#8221;) as adjunctive therapy (VEGA-1). We reported top-line data from a Phase 3 trial in DLD in May&#160;2022 (LYNX-1). The VEGA-2 Phase 3 study in presbyopia achieved its primary endpoint and Viatris, our development and commercial partner, is expected to continue Phase 3 development in the first half of 2024. For DLD, a SPA has been submitted and Viatris is also expected to continue Phase 3 development in the first half of 2024 following FDA agreement. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">Recent Developments </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 7pt; margin-left: 0pt; text-align: left;">Clinical Milestones </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 12pt; margin-left: 0pt; text-align: left;">APX3330 </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In January&#160;2023, we announced top-line efficacy and safety results from ZETA-1, a Phase 2b trial of APX3330 in diabetic retinopathy patients. In ZETA-1, APX3330 demonstrated favorable safety and tolerability and exhibited efficacy in slowing or prevention of DR worsening on a binocular DRSS Person Scale. The FDA agreed this was an approvable registration endpoint at our EOP2 meeting. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">2<br></div></div></div>
<!--End Page 25-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 26-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_203-summary_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Phentolamine Ophthalmic Solution 0.75% (POS) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In January&#160;2023, we announced the initiation of the VEGA-2 Phase 3 pivotal trial, the first of two Phase 3 registration trials intended to support a presbyopia indication for POS alone and POS with LDP. The VEGA-2 Phase 3 study achieved its primary endpoint and Viatris, our development and commercial partner, is expected to continue Phase 3 development in the first half of 2024. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Regulatory Update </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In September&#160;2023, we announced FDA approval of POS under the brand name RYZUMVI&#8482; for the treatment of RM; for this approval we received a $10&#160;million milestone payment under the Nyxol License Agreement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In October&#160;2023, a SPA was submitted to the FDA for DLD and Viatris, our development and commercial partner, is expected to continue Phase 3 development in the first half of 2024 following FDA agreement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In November&#160;2023, we announced the successful outcome of the EOP2 meeting with the FDA, at which we obtained agreement on the registration endpoint supporting the advancement of APX3330 into Phase 3. Ocuphire plans to submit a SPA to agree on the clinical trial protocol and statistical analysis plan for the Phase 3 trials and will share specifics on the study design parameters and anticipated timing once agreed with the FDA. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Management Transitions </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;1, 2023, the Company announced the appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and member of the Board of Directors. As a result of such appointment, Richard Rodgers, who was serving as Interim President and Chief Executive Officer, resigned from such position and remains on the Board. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On November&#160;27, 2023, the Company announced the appointment of Joseph K. Schachle, as Chief Operating Officer. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Purchase Agreement with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">On August&#160;10, 2023, we entered into a common stock purchase agreement (the &#8220;Purchase Agreement&#8221;) with Lincoln Park, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Ocuphire has the sole right, but not the obligation, to direct Lincoln Park to purchase up to $50&#160;million of shares of our common stock, par value $0.0001 (the &#8220;Common Stock&#8221;), from time to time over the 30-month term of the Purchase Agreement. Concurrently with entering into the Purchase Agreement, Ocuphire also entered into a registration rights agreement with Lincoln Park (the &#8220;Registration Rights Agreement&#8221;), pursuant to which we agreed to register the resale of the shares of our Common Stock that have been and may be issued to Lincoln Park under the Purchase Agreement pursuant to a registration statement. Upon the execution of the Purchase Agreement, we issued 246,792 shares of Common Stock to Lincoln Park as consideration for its commitment to purchase shares of our Common Stock under the Purchase Agreement. Lincoln Park has agreed not to cause or engage in any manner whatsoever in any direct or indirect short selling or hedging of our Common Stock. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 16.5pt; margin-left: 0pt; text-align: left;">Global Economic Conditions </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Generally, worldwide economic conditions remain uncertain, particularly due to the effects of the conflict between Russia and Ukraine and potentially between Israel and Hamas, disruptions in the banking system and financial markets, lingering COVID-19 pandemic, increased inflation and increased interest rates. The general economic and capital market conditions, both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected our access to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising activity on favorable terms. If economic conditions decline, our future cost of equity or debt capital and access to the capital markets could be adversely affected. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Additionally, our operating results could be materially impacted by changes in the overall macroeconomic environment and other economic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflicts in Ukraine and the Middle East, disruptions in the banking system and financial markets, and steps taken by governments and central banks, particularly in response to the COVID-19 pandemic as well as other stimulus and spending programs, have led to higher inflation, which has led to an increase in costs and has caused changes in fiscal and monetary policy, including increased interest rates. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">3<br></div></div></div>
<!--End Page 26-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 27-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_203-summary_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Risks Associated with our Business </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our business is subject to numerous risks, as described under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into this prospectus. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Description of Securities We May Offer </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may offer shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, with a total dollar amount up to $175,000,000 from time to time under this prospectus, together with the applicable prospectus supplement and any related free writing prospectus, at prices and on terms to be determined at the time of any offering. We may also offer common stock, preferred stock and/or debt securities upon the exercise of warrants. This prospectus provides you with a general description of the securities we may offer. Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">designation or classification; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">aggregate principal amount or aggregate offering price; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maturity; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">original issue discount; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">rates and times of payment of interest or dividends; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">redemption, conversion, exercise, exchange or sinking fund terms; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">ranking; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictive covenants; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">voting or other rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">conversion or exchange prices or rates and, if applicable, any provisions for changes to or adjustments in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a discussion of material United States federal income tax considerations, if any. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may sell the securities directly to investors or to or through agents, underwriters or dealers. We, and our or their agents, underwriters or dealers reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents, underwriters or dealers, we will include in the applicable prospectus supplement: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the names of those agents, underwriters or dealers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">applicable fees, discounts and commissions to be paid to them; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">details regarding over-allotment options, if any; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the net proceeds to us, if any. </div></td></tr></table></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">4<br></div></div></div>
<!--End Page 27-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 28-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_203-summary_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue shares of our common stock from time to time. Each holder of our common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Under our amended and restated certificate of incorporation, as amended, or certificate of incorporation, and second amended and restated bylaws, or bylaws, our stockholders do not have cumulative voting rights. Because of this, the holders of a majority of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, holders of common stock are entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock. Holders of common stock have no preemptive, conversion or subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future. In this prospectus, we have summarized certain general features of the common stock under &#8220;Description of Capital Stock&#8212;Common Stock.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Preferred Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue shares of our preferred stock from time to time, in one or more series. Our board of directors will determine the designations, voting powers, preferences and rights of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series, or the designation of such series, any or all of which may be greater than the rights of our common stock. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities. Conversion may be mandatory or at your option and would be at prescribed conversion rates. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If we sell any series of preferred stock under this prospectus, we will fix the designations, voting powers, preferences and rights of such series of preferred stock, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock that we are offering before the issuance of the related series of preferred stock. In this prospectus, we have summarized certain general features of the preferred stock under &#8220;Description of Capital Stock&#8212;Preferred Stock.&#8221; We urge you to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable series of preferred stock. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 18pt; margin-left: 0pt; text-align: left;">Debt Securities </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible or exchangeable debt securities will be convertible into or exchangeable for our common stock or our other securities. Conversion or exchange may be mandatory or optional (at our option or the holders&#8217; option) and would be at prescribed conversion or exchange rates. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any debt securities issued under this prospectus will be issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities under &#8220;Description of Debt Securities.&#8221; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">5<br></div></div></div>
<!--End Page 28-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 29-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 492pt;"><a name="ny20058362x1_424b5_203-summary_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_border-box" style="border-top: 1pt solid #000000; border-left: 1pt solid #000000; border-right: 1pt solid #000000; border-bottom: 1pt solid #000000; margin-bottom: 12pt; padding-top: 12pt; padding-bottom: 12pt; width: 492pt; margin-left: 0pt;"><div class="BRDSX_page-content" style="margin-left: 12pt;"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">well as the complete indenture and any supplemental indentures that contain the terms of the debt securities. A&#160;form of indenture has been filed as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Warrants </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or in combination with common stock, preferred stock and/or debt securities offered by any prospectus supplement. In this prospectus, we have summarized certain general features of the warrants under &#8220;Description of Warrants.&#8221; We urge you, however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as any warrant agreements and warrant certificates, as applicable, that contain the terms of the warrants. We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any warrants issued under this prospectus may be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Use of Proceeds </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from this offering for working capital and general corporate purposes, which may include, among other things, funding research and development programs, vendor payables, hiring additional personnel, and capital expenditures. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Company Information </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our principal executive offices are located at 37000 Grand River Avenue, Suite 120, Farmington Hills, MI&#160;48335. Our telephone number is (248) 957-9024. Our website address is www.ocuphire.com. The information contained in, or accessible through, our website does not constitute part of this prospectus, should not be relied on in determining whether to make an investment decision, and the inclusion of our website address in this prospectus is an inactive textual reference only. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Implications of Being a Smaller Reporting Company </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We are a &#8220;smaller reporting company&#8221; under federal securities laws. For as long as we continue to be a smaller reporting company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies, including, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250&#160;million or (ii) our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700&#160;million. As long as we remain a smaller reporting company and non-accelerated filer, we are exempt from the attestation requirement in the assessment of our internal control over financial reporting by our independent auditors pursuant to section 404(b) of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) but are required to make our own internal assessment of the effectiveness of our internal controls over financial reporting. </div></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 12pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">6<br></div></div></div>
<!--End Page 29-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 30-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_204-risk_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tRF"><!--Anchor--></a>RISK FACTORS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks of investing in our securities discussed under the heading &#8220;Risk Factors&#8221; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our financial statements, and the exhibits to the registration statement of which this prospectus is a part, and which may be amended, supplemented or superseded from time to time by other reports we file with the SEC in the future.<font style="font-style: normal;"> </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. Please also read carefully the section below entitled &#8220;Forward-Looking Statements.&#8221;<font style="font-style: normal;"> </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">7<br></div></div></div>
<!--End Page 30-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 31-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_205-fls_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tFLS"><!--Anchor--></a>FORWARD-LOOKING STATEMENTS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus and the documents we have filed with the SEC that are incorporated by reference contain &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, forward-looking statements may be identified by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. You should refer to the &#8220;Risk Factors&#8221; section contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Given these risks, uncertainties and other factors, many of which are beyond our control, we cannot assure you that the forward-looking statements in this prospectus will prove to be accurate, and you should not place undue reliance on these forward-looking statements. These risks include, among other things, that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we currently depend entirely on the success of Phentolamine Ophthalmic Solution 0.75% (POS) and APX3330, our only product candidates, and we may never complete clinical development of, receive marketing approval for, or successfully commercialize, POS alone or as adjunctive therapy with low dose pilocarpine (LDP), APX3330, or other product candidates we may pursue in the future for any indication; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">Viatris has exclusive rights to commercialize our POS products in key global markets and Viatris&#8217; failure to timely develop or commercialize these products would have a material adverse effect on our business and operating results; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">changes in regulatory requirements or FDA guidance, or unanticipated events during our clinical trials, may result in changes to clinical trial protocols or additional clinical trial requirements, which could result in increased costs to us or delays in our development timelines; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we expect to incur losses for the foreseeable future and may never achieve or maintain profitability; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adverse global economic conditions could have a negative effect on our business results of operations and financial condition and liquidity; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">adverse developments affecting the financial services industry could negatively affect our current and projected business operations, financial condition and results of operations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">even if we receive marketing approval for our product candidates in the United States, we may never receive regulatory approval to market such product candidates outside of the United States; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our employees or our representatives may engage in misconduct or other improper activities, including violating applicable regulatory standards and requirements or engaging in insider trading, which could significantly harm our business; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">8<br></div></div></div>
<!--End Page 31-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 32-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_205-fls_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we lack experience in commercializing products, which may have an adverse effect on our business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell, market, and distribute APX3330, if approved, we may not be successful in commercializing APX3330 if and when it is approved; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">product liability lawsuits against us, or our suppliers and manufacturers, could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we are unable to control all aspects of our clinical trials due to our reliance on clinical research organizations, contract development and manufacturing organizations and other third parties that assist us in conducting clinical trials; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we are unable to control the supply, manufacture and testing of bulk drug substances and the formulation, testing and packaging of preclinical and clinical drug supplies of our product candidates, and will be unable to control these elements at the commercial stage, due to our reliance on third-party manufacturers and analytical facilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we are not able to establish new collaborations for APX3330 on commercially reasonable terms, we may have to alter our development, manufacturing, and commercialization plans; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we are unable to obtain and maintain sufficient patent protection for our product candidates, our competitors could develop and commercialize products or technology similar or identical to ours, which would adversely affect our ability to successfully commercialize any product candidates we may develop, our business, results of operations, financial condition and prospects; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may not be able to protect or practice our intellectual property rights throughout the world; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we depend on intellectual property sublicensed from Apexian Pharmaceuticals, Inc. (&#8220;Apexian&#8221;) for our APX3330 product candidate under development and our additional pipeline candidates, and the termination of, or reduction or loss of rights under, this sublicense would harm our business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we will need to develop and expand our company and may encounter difficulties in managing this development and expansion, which could disrupt our operations; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our insurance policies are expensive and protect only from some business risk, which leaves us exposed to significant uninsured liabilities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">environmental, social, and governance matters and any related reporting obligations may impact our business; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we fail to comply with the continued listing standards of the Nasdaq Capital Market, our common stock could be delisted. If it is delisted, our common stock price and the liquidity of our common stock would be impacted; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the market price of our common stock may fluctuate significantly; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we may be subject to securities litigation, which is expensive and could divert management attention; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">there is uncertainty regarding the use of proceeds, if any, from this offering. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">9<br></div></div></div>
<!--End Page 32-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 33-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_205-fls_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">These risks are not exhaustive. Other sections of this prospectus may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties nor can we assess the impact of all such factors on our business or the extent to which any such factor, or combination of such factors, may cause actual results to differ from those contained in, or implied by, any forward-looking statements. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus or to conform these statements to actual results or to changes in our expectations. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, &#8220;we believe&#8221; and &#8220;we expect&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">You should read this prospectus and the documents that we reference in this prospectus and have filed as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">10<br></div></div></div>
<!--End Page 33-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 34-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_206-use_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tUP"><!--Anchor--></a>USE OF PROCEEDS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from this offering for working capital and general corporate purposes, which may include, among other things, funding research and development programs, vendor payables, hiring additional personnel, and capital expenditures. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">11<br></div></div></div>
<!--End Page 34-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 35-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDCS"><!--Anchor--></a>DESCRIPTION OF CAPITAL STOCK </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 13pt; margin-left: 0pt; text-align: left;">General </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of the date of this prospectus, our certificate of incorporation authorizes us to issue up to 85,000,000 shares of capital stock, all with a par value of $0.0001 per share, of which: 75,000,000 shares are designated as common stock and 10,000,000 shares are designated as preferred stock.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following summary describes the material terms of our capital stock. The description of capital stock is qualified by reference to our certificate of incorporation and our bylaws. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14pt; margin-left: 0pt; text-align: left;">Common Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of September&#160;30, 2023, 22,610,131 shares of common stock were outstanding. All outstanding shares of common stock are duly authorized, validly issued, fully paid, and nonassessable. All authorized but unissued shares of our common stock are available for issuance by our board of directors without any further stockholder action, except as required by the listing standards of Nasdaq. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Voting Rights</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Dividend Rights</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14pt; margin-left: 0pt; text-align: left;">Liquidation</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In the event of our liquidation, dissolution, or winding up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred stock then-outstanding. </div><div class="BRDSX_h4" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Rights and Preferences</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking fund provisions applicable to the common stock. The rights, preferences, and privileges of holders of common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 14.5pt; margin-left: 0pt; text-align: left;">Preferred Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of September&#160;30, 2023, no shares of preferred stock were outstanding. Our board of directors may, without further action by our stockholders, fix the rights, preferences, privileges and restrictions of up to an aggregate of 10,000,000 shares of preferred stock in one or more series and authorize their issuance. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of our common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of decreasing the market price of our common stock and could also have the effect of delaying, deferring or preventing a change of control or other corporate action.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will fix the designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration statement of which this prospectus </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">12<br></div></div></div>
<!--End Page 35-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 36-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that describes the terms of the series of preferred stock we are offering. We will describe in the applicable prospectus supplement the terms of the series of preferred stock being offered, including, to the extent applicable: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the title and stated value; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the number of shares we are offering; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the liquidation preference per share; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the purchase price; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the dividend rate, period and payment date and method of calculation for dividends; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the procedures for any auction and remarketing; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the provisions for a sinking fund; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any listing of the preferred stock on any securities exchange or market; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or how it will be calculated, and the exchange period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">voting rights of the preferred stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">preemptive rights; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">restrictions on transfer, sale or other assignment; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether interests in the preferred stock will be represented by depositary shares; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a discussion of material United States federal income tax considerations applicable to the preferred stock; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">If we issue shares of preferred stock under this prospectus, the shares will be fully paid and non-assessable. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Options and Restricted Stock </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of September&#160;30, 2023, (i) 1,016,033 shares of common stock remain available for issuance under our 2020&#160;Plan and 2021 Inducement Plan, stock options to purchase an aggregate of 2,249,950 shares of common stock were outstanding under our 2020 Equity Incentive Plan, or 2020 Plan, stock options to purchase an aggregate of 133,000 shares of common stock were outstanding under our 2021 Inducement Plan, and stock options to purchase an aggregate of 1,086,439 shares of common stock were outstanding under our 2018 Equity Incentive Plan, or 2018 Plan, and (ii) 282,008 unvested shares of restricted stock were outstanding. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Warrants </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As of September&#160;30, 2023, 7,262,896 warrants to purchase shares of our capital stock were outstanding, with a weighted average exercise price of $5.09 (subject to adjustment). </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">13<br></div></div></div>
<!--End Page 36-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 37-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our amended and restated certificate of incorporation and second amended and restated bylaws contain provisions that could make it more difficult to complete an acquisition of us by means of a tender offer, a proxy contest or otherwise or the removal and replacement of our incumbent officers and directors. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Removal of Directors; Board Vacancies; Board Size<font style="font-style: normal;">. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and requires a stockholder vote of at least a majority of the voting power of the then outstanding voting stock. In addition, our amended and restated certificate of incorporation provides that any vacancy occurring on our board of directors may be filled by a majority of directors then in office, even if less than a quorum, unless the board of directors determines that such vacancy shall be filled by the stockholders. Finally, the authorized number of directors may be changed only by a resolution of the board of directors. This system of removing directors, filling vacancies and fixing the size of the board makes it more difficult for stockholders to replace a majority of the directors. </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Special Stockholder Meetings.<font style="font-style: normal;"> Our amended and restated certificate of incorporation and our second amended and restated bylaws provide that a special meeting of stockholders may be called only by a resolution adopted by a majority of our board of directors or by the chairman of the board. </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Stockholder Advance Notice Procedure.<font style="font-style: normal;"> Our second amended and restated bylaws establish an advance notice procedure for stockholders to make nominations of candidates for election as directors or to bring other business before an annual meeting of our stockholders. The second amended and restated bylaws provide that any stockholder wishing to nominate persons for election as directors at, or bring other business before, an annual meeting must deliver to our secretary a written notice of the stockholder&#8217;s intention to do so. To be timely, the stockholder&#8217;s notice must be delivered to or mailed and received by us not more than 120 days, and not less than 90 days before the anniversary date of the preceding annual meeting, except that if the annual meeting is set for a date that is not within 30 days before or 60 days after such anniversary date, we must receive the notice not earlier than the close of business on the 120th day prior to the annual meeting and not later than the close of business on the later of (i) the 90th day prior to the annual meeting or (ii) the tenth day following the day on which we first made public announcement of the date of meeting. The notice must include the following information: </font></div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as to director nominations, all information relating to each director nominee that is required by the rules of the Securities and Exchange Commission to be disclosed in solicitations of proxies, or is otherwise required by Regulation 14A of the Exchange Act; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business to be proposed, the reasons for conducting such business at the meeting and, if any, the stockholder&#8217;s material interest in the proposed business; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the name and address of the stockholder who intends to make the nomination and the class and number of our shares beneficially owned of record; </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Undesignated Preferred Stock. <font style="font-style: normal;">The ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could have the effect of delaying, deferring, preventing or otherwise impeding any attempt to change control of us. </font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Delaware Anti-Takeover Statute.<font style="font-style: normal;"> We are subject to Section&#160;203 of the Delaware General Corporation Law, which prohibits persons deemed &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly traded Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock.</font></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; margin-top: 6pt; margin-left: 0pt; text-align: left;">Business Combinations with Interested Stockholders<font style="font-style: normal;">. Our amended and restated certificate of incorporation provides that certain &#8220;business combinations&#8221; with &#8220;interested stockholders&#8221; require approval by the holders of </font></div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">14<br></div></div></div>
<!--End Page 37-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 38-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg4"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">at least a majority of the voting power of our then outstanding shares of voting stock not beneficially owned by any interested stockholder or an affiliate or associate thereof. The foregoing restriction does not apply, however, if the transaction is either approved by a majority of our &#8220;continuing directors&#8221; or certain minimum price and procedural and other requirements are met. Generally, a &#8220;business combination&#8221; includes a merger, consolidation, liquidation, recapitalization or other similar transaction or a sale, lease, transfer or other disposition of assets or securities having an aggregate fair market value of $15&#160;million or more. An &#8220;interested stockholder&#8221; generally means a beneficial owner of 20% or more of our voting stock, certain assignees of such beneficial owners and certain of our affiliates that within the preceding two years were the beneficial owner of 20% or more of our voting stock. A &#8220;continuing director&#8221; is defined as any member of our board who is not an affiliate or associate or representative of the interested stockholder and was a member of the board prior to the time the interested stockholder became such, and any successor of a continuing director who is unaffiliated with the interested stockholder and is recommended or elected by at least two-thirds of the continuing directors then on the board. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Transfer Agent and Registrar </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">The transfer agent and registrar for our common stock is Equiniti Trust Company. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Listing on the Nasdaq Capital Market </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">Our common stock is listed on the Nasdaq Capital Market under the symbol &#8220;OCUP.&#8221; </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">15<br></div></div></div>
<!--End Page 38-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 39-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg5"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDBS"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to any supplemental indentures that specify the terms of a particular series of debt securities.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will issue the debt securities under the indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following summary of material provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">General </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The indenture does not limit the amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against changes in our operations, financial condition or transactions involving us.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue the debt securities issued under the indenture as &#8220;discount securities,&#8221; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#8220;original issue discount,&#8221; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be described in more detail in any applicable prospectus supplement.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will describe in the applicable prospectus supplement the terms of the series of debt securities being offered, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the title of the series of debt securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any limit upon the aggregate principal amount that may be issued; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the maturity date or dates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the form of the debt securities of the series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the applicability of any guarantees; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination thereof, and the terms of any subordination; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 5pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt securities that is convertible into another security or the method by which any such portion shall be determined; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">16<br></div></div></div>
<!--End Page 39-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 40-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg6"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our right, if any, to defer payment of interest and the maximum length of any such deferral period; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and any integral multiple thereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in part for other individual securities; and the depositary for such global security or securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the holders&#8217; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the series which shall be payable upon declaration of acceleration of the maturity thereof; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the covenants applicable to the particular debt securities being issued, including, among others, the consolidation, merger or sale covenant; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the events of default with respect to the securities and any change in the right of the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the provisions relating to satisfaction and discharge of the indenture; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">additions to or changes in the provisions relating to the modification of the indenture both with and without the consent of holders of debt securities issued under the indenture; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the equivalent amount in U.S. dollars; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether interest will be payable in cash or additional debt securities at our or the holders&#8217; option and the terms and conditions upon which the election may be made; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if any and principal amounts of the debt securities of the series to any holder that is not a &#8220;United States person&#8221; for federal tax purposes; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any restrictions on transfer, sale or assignment of the debt securities of the series; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 4pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">17<br></div></div></div>
<!--End Page 40-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 41-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg7"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Conversion or Exchange Rights </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of debt securities receive would be subject to adjustment. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Consolidation, Merger or Sale </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Events of Default under the Indenture </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following are events of default under the indenture with respect to any series of debt securities that we may issue: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of interest for this purpose; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90 days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if specified events of bankruptcy, insolvency or reorganization occur. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If an event of default with respect to debt securities of any series occurs and is continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us, the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any waiver shall cure the default or event of default.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">18<br></div></div></div>
<!--End Page 41-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 42-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg8"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the direction so given by the holder is not in conflict with any law or the applicable indenture; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A holder of the debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holder has given written notice to the trustee of a continuing event of default with respect to that series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have made written request; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities to be incurred by the trustee in compliance with the request; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series other conflicting directions within 90 days after the notice, request and offer. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will periodically file statements with the trustee regarding our compliance with specified covenants in the indenture. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Modification of Indenture; Waiver </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to comply with the provisions described above under &#8220;Description of Debt Securities&#8212;Consolidation, Merger or Sale;&#8221; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to provide for uncertificated debt securities in addition to or in place of certificated debt securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default or to surrender any right or power conferred upon us in the indenture; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms, or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to make any change that does not adversely affect the interests of any holder of debt securities of any series in any material respect; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any series as provided above under &#8220;Description of Debt Securities&#8212;General&#8221; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the rights of the holders of any series of debt securities; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">19<br></div></div></div>
<!--End Page 42-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 43-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg9"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust Indenture Act. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">extending the fixed maturity of any debt securities of any series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any premium payable upon the redemption of any series of any debt securities; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment, supplement, modification or waiver. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Discharge </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for specified obligations, including obligations to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">provide for payment; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">register the transfer or exchange of debt securities of the series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">replace stolen, lost or mutilated debt securities of the series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">pay principal of and premium and interest on any debt securities of the series; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">maintain paying agencies; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">hold monies for payment in trust; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">recover excess money held by the trustee; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">compensate and indemnify the trustee; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">appoint any successor trustee. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In order to exercise our rights to be discharged, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 17.5pt; margin-left: 0pt; text-align: left;">Form, Exchange and Transfer </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book-entry securities will be set forth in the applicable prospectus supplement.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">20<br></div></div></div>
<!--End Page 43-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 44-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg10"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">by us or the security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">If we elect to redeem the debt securities of any series, we will not be required to: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Information Concerning the Trustee </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it might incur. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Payment and Paying Agents </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Governing Law </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The indenture and the debt securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">21<br></div></div></div>
<!--End Page 44-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 45-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg11"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tDW"><!--Anchor--></a>DESCRIPTION OF WARRANTS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The following description, together with the additional information we may include in any applicable prospectus supplement and free writing prospectus, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock or debt securities and may be issued in one or more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this prospectus, as well as any related free writing prospectus, and the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20pt; margin-left: 0pt; text-align: left;">General </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7pt; margin-left: 0pt; text-align: left;">We will describe in the applicable prospectus supplement the terms of the series of warrants being offered, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the offering price and aggregate number of warrants offered; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the currency for which the warrants may be purchased; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if applicable, the designation and terms of the securities with which the warrants are issued and the number of warrants issued with each such security or each principal amount of such security; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and the warrants; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of any rights to redeem or call the warrants; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise of the warrants; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the dates on which the right to exercise the warrants will commence and expire; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the manner in which the warrant agreements and warrants may be modified; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the warrants; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the terms of the securities issuable upon exercise of the warrants; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any other specific terms, preferences, rights or limitations of or restrictions on the warrants. </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">22<br></div></div></div>
<!--End Page 45-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 46-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_207-description_pg12"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium, if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or, payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Exercise of Warrants </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price that we describe in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be exercised at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Governing Law </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless we otherwise specify in the applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Enforceability of Rights by Holders of Warrants </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">23<br></div></div></div>
<!--End Page 46-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 47-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_208-ownership_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLOS"><!--Anchor--></a>LEGAL OWNERSHIP OF SECURITIES </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#8220;holders&#8221; of those securities. These persons are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#8220;indirect holders&#8221; of those securities. As we discuss below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Book-Entry Holders </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#8217;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">As a result, investors in a global security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker or other financial institution that participates in the depositary&#8217;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not legal holders, of the securities. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Street Name Holders </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may terminate a global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in &#8220;street name.&#8221; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For securities held in street name, we or any applicable trustee or depositary will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we or any applicable trustee or depositary will make all payments on those securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; margin-left: 0pt; text-align: left;">Legal Holders </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">For example, once we make a payment or give a notice to the legal holder, we have no further responsibility for the payment or notice even if that legal holder is required, under agreements with its participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the approval of the legal holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the holders, and not the indirect holders, of the securities. Whether and how the legal holders contact the indirect holders is up to the legal holders. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">24<br></div></div></div>
<!--End Page 47-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 48-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_208-ownership_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Special Considerations For Indirect Holders </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If you hold securities through a bank, broker or other financial institution, either in book-entry form because the securities are represented by one or more global securities or in street name, you should check with your own institution to find out: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">how it handles securities payments and notices; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether it imposes fees or charges; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">how it would handle a request for the holders&#8217; consent, if ever required; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the securities are in book-entry form, how the depositary&#8217;s rules and procedures will affect these matters. </div></td></tr></table><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Global Securities </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each security issued in book-entry form will be represented by a global security that we issue to, deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under &#8220;Special Situations When a Global Security Will Be Terminated.&#8221; As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and legal holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a legal holder of the security, but only an indirect holder of a beneficial interest in the global security.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held through any book-entry clearing system. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 15pt; margin-left: 0pt; text-align: left;">Special Considerations for Global Securities </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#8217;s financial institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8pt; margin-left: 0pt; text-align: left;">If securities are issued only in the form of a global security, an investor should be aware of the following: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an investor cannot cause the securities to be registered in his or her name, and cannot obtain non-global certificates for his or her interest in the securities, except in the special situations we describe below; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an investor will be an indirect holder and must look to his or her own bank, broker or other financial institution for payments on the securities and protection of his or her legal rights relating to the securities, as we describe above; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; </div></td></tr></table></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">25<br></div></div></div>
<!--End Page 48-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 49-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_208-ownership_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6.75pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">an investor may not be able to pledge his or her interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the depositary&#8217;s policies, which may change from time to time, will govern payments, transfers, exchanges and other matters relating to an investor&#8217;s interest in a global security; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">we and any applicable trustee have no responsibility for any aspect of the depositary&#8217;s actions or for its records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your bank, broker or other financial institution may require you to do so as well; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">financial institutions that participate in the depositary&#8217;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities.</div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the actions of any of those intermediaries. </div><div class="BRDSX_h2" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; margin-left: 0pt; text-align: left;">Special Situations when a Global Security will be Terminated </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks, brokers or other financial institutions to find out how to have their interests in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations occur: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary within 90 days; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if we notify any applicable trustee that we wish to terminate that global security; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The applicable prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">26<br></div></div></div>
<!--End Page 49-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 50-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_209-plan_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tPD"><!--Anchor--></a>PLAN OF DISTRIBUTION </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 7.5pt; margin-left: 0pt; text-align: left;">We may sell our securities covered by this prospectus in any of three ways (or in any combination): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">to or through underwriters or dealers; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">directly to one or more purchasers; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">through agents. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; margin-left: 0pt; text-align: left;">We may distribute the securities: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">from time to time in one or more transactions at a fixed price or prices, which may be changed from time to time; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at market prices prevailing at the time of sale; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at prices related to the prevailing market prices; or </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">at negotiated prices. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Each time we offer and sell securities covered by this prospectus, we will provide a prospectus supplement or supplements, if necessary, that will describe the method of distribution and set forth the terms of the offering, including: </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the name or names of any underwriters, dealers or agents; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the amounts of securities underwritten or purchased by each of them; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the purchase price of securities and the proceeds, if any, we will receive from the sale; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any over-allotment options under which underwriters may purchase additional securities from us; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any underwriting discounts or commissions or agency fees and other items constituting underwriters&#8217; or agents&#8217; compensation; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the public offering price of the securities; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any discounts, commissions or concessions allowed or reallowed or paid to dealers; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">any securities exchange or market on which the securities may be listed. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. We may determine the price or other terms of the securities offered under this prospectus by use of an electronic auction. We will describe how any auction will determine the price or any other terms, how potential investors may participate in the auction and the nature of the obligations of the underwriter, dealer or agent in the applicable prospectus supplement.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Underwriters or dealers may offer and sell the offered securities from time to time in one or more transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. If underwriters or dealers are used in the sale of any securities, the securities will be acquired by the underwriters or dealers for their own account and may be resold from time to time in one or more transactions described above. The securities may be either offered to the public through underwriting syndicates represented by managing underwriters, or directly by underwriters or dealers. Generally, the underwriters&#8217; or dealers&#8217; obligations to purchase the securities will be subject to certain conditions precedent. The underwriters or dealers will be obligated to purchase all of the securities if they purchase any of the securities, unless otherwise specified in the prospectus supplement. We may use underwriters with whom we have a material relationship. We will describe the nature of any such relationship in the prospectus supplement, naming the underwriter.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We may sell the securities through agents from time to time. The prospectus supplement will name any agent involved in the offer or sale of the securities and any commissions we pay to them. Generally, any agent will be acting on a best efforts basis for the period of its appointment. We may authorize underwriters, dealers or agents to solicit offers by certain purchasers to purchase the securities from us at the public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The contracts will be subject only to those conditions set forth in the prospectus supplement, and the prospectus supplement will set forth any commissions we pay for solicitation of these contracts.</div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">27<br></div></div></div>
<!--End Page 50-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 51-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_209-plan_pg2"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fapra" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">Agents, dealers and underwriters may be entitled to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments which the agents, dealers or underwriters may be required to make in respect thereof. Agents, dealers and underwriters may be customers of, engage in transactions with, or perform services for us in the ordinary course of business.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">All securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation M under the Securities Exchange Act of 1934, as amended. Overallotment involves sales in excess of the offering size, which create a short position. This short sales position may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales. Covered short sales are short sales made in an amount not greater than the underwriters&#8217; over-allotment option to purchase additional securities in this offering described above. The underwriters may close out any covered short position either by exercising their over-allotment option or by purchasing securities in the open market. To determine how they will close the covered short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market, as compared to the price at which they may purchase securities through the over-allotment option. Naked short sales are short sales in excess of the over-allotment option. The underwriters must close out any naked short position by purchasing securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that, in the open market after pricing, there may be downward pressure on the price of the securities that could adversely affect investors who purchase securities in this offering. Stabilizing transactions permit bids to purchase the underlying security for the purpose of fixing the price of the security so long as the stabilizing bids do not exceed a specified maximum. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a covering transaction to cover short positions.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any underwriters who are qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in our common stock, preferred stock, warrants and debt securities, as applicable, on the Nasdaq Capital Market in accordance with Rule&#160;103 of Regulation M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if all independent bids are lowered below the passive market maker&#8217;s bid, however, the passive market maker&#8217;s bid must then be lowered when certain purchase limits are exceeded.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Any broker-dealer participating in the distribution of the shares of common stock may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of common stock is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of shares of common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Under the securities laws of some states, the shares of common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">In compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities offered pursuant to this prospectus and any applicable prospectus supplement.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Similar to other purchase transactions, an underwriter&#8217;s purchase to cover the syndicate short sales or to stabilize the market price of our securities may have the effect of raising or maintaining the market price of our securities </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">28<br></div></div></div>
<!--End Page 51-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 52-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_209-plan_pg3"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6.75pt; margin-left: 0pt; text-align: left;">or preventing or mitigating a decline in the market price of our securities. As a result, the price of our securities may be higher than the price that might otherwise exist in the open market. The imposition of a penalty bid might also have an effect on the price of the securities if it discourages resales of the securities.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Neither we nor the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of the securities. If such transactions are commenced, they may be discontinued without notice at any time.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will pay all expenses of the registration of the shares of common stock pursuant to the waiver agreements, including, without limitation, Securities and Exchange Commission filing fees and expenses of compliance with state securities or &#8220;blue sky&#8221; laws.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Once sold under the registration statement, of which this prospectus forms a part, the shares of common stock will be freely tradable in the hands of persons other than our affiliates. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">29<br></div></div></div>
<!--End Page 52-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 53-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_210-legal_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tLM"><!--Anchor--></a>LEGAL MATTERS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered by this prospectus, and any supplement thereto, will be passed upon for us by Honigman LLP. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tEXP"><!--Anchor--></a>EXPERTS </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The consolidated financial statements of Ocuphire Pharma, Inc. appearing in Ocuphire Pharma, Inc.&#8217;s Annual&#160;Report (Form&#160;10-K) for the year ended December&#160;31, 2022 have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon included therein, and incorporated herein by reference. Such consolidated financial statements are, and audited financial statements to be included in subsequently filed documents will be, incorporated herein in reliance upon such report of Ernst &amp; Young LLP pertaining to such financial statements (to the extent covered by consents filed with the Securities and Exchange Commission) given on the authority of such firm as experts in accounting and auditing. </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 20.5pt; text-align: center;"><a name="tWYC"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">This prospectus is part of a registration statement we filed with the SEC. This prospectus does not contain all of the information set forth in the registration statement and the exhibits to the registration statement. For further information with respect to us and the securities we are offering under this prospectus, we refer you to the registration statement and the exhibits and schedules filed as a part of the registration statement. Neither we nor any agent, underwriter or dealer has authorized any person to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front page of this prospectus, regardless of the time of delivery of this prospectus or any sale of the securities offered by this prospectus.</div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC, including Ocuphire. The address of the SEC website is www.sec.gov. </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We maintain a website at www.ocuphire.com. Information contained in or accessible through our website does not constitute a part of this prospectus. </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">30<br></div></div></div>
<!--End Page 53-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 54-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 468pt;"><a name="ny20058362x1_424b5_211-incorp_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 468pt; margin-left: 0pt;"><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 6.75pt; text-align: center;"><a name="tICI"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring you to those documents instead of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. We incorporate by reference the documents listed below and any future filings (including those made after the date of the initial filing of the registration statement of which this prospectus is a part and prior to the effectiveness of such registration statement) we will make with the SEC under Sections 13(a), 13(c), 14, or&#160;15(d) of the Exchange Act until the termination of the offering of the shares covered by this prospectus (other&#160;than information furnished under Item&#160;2.02 or Item&#160;7.01 of Form&#160;8-K): </div><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036123014868/brhc10050364_10k.htm">March&#160;30, 2023</a>, and the information specifically incorporated by reference into our Definitive Proxy Statement on Schedule 14A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036123022044/ny20008514x2_def14a.htm">May&#160;1, 2023</a>; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Quarterly Reports on Form&#160;10-Q for the quarters ended March&#160;31, 2023, June&#160;30, 2023, and September&#160;30, 2023 filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123024504/brhc20052759_10q.htm">May&#160;15, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036123039196/brhc20057115_10q.htm">August&#160;11, 2023</a>, and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036123052749/ef20012451_10q.htm">November&#160;13, 2023</a> respectively; </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">our Current Reports on Form&#160;8-K filed with the SEC on <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123002726/brhc10046995_8k.htm">January&#160;25, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123019505/brhc20051717_8k.htm">April&#160;21, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123028066/brhc20053954_8k.htm">June&#160;2, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123029009/brhc20054226_8k.htm">June&#160;9, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123029848/brhc20054327_8k.htm">June&#160;14, 2023</a>, <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123039201/brhc20057386_8k.htm">August&#160;11, 2023</a>; <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123045418/ef20011305_8k.htm">September&#160;27, 2023</a>; <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123050844/ef20013742_8k.htm">November&#160;1, 2023</a>; <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001228627/000114036123051009/ef20013910_8k.htm">November&#160;2, 2023</a>; <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036123054632/ef20015189_8k.htm">November&#160;27, 2023</a>; and <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1228627/000114036123056425/ef20015996_8k.htm">December&#160;6, 2023</a>; and </div></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="margin-top: 6pt; margin-left: 20pt;"><tr><td style="width: 20pt; text-align: left; vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8226;</div></td><td style="vertical-align: top;"><div style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">the description of common stock set forth in the Registration Statement on Form&#160;8-A, filed with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036119010684/form8a12b.htm">June&#160;7, 2019</a>, including any amendments thereto or reports filed for the purposes of updating this description, as updated by <a href="https://www.sec.gov/Archives/edgar/data/1228627/000114036121008099/brhc10021462_ex4-11.htm">Exhibit&#160;4.6</a> to our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022, filed with the SEC on March&#160;30, 2023, including any amendments or reports filed for the purposes of updating this description. </div></td></tr></table><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 6pt; margin-left: 0pt; text-align: left;">We will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You may request a copy of these documents by writing or telephoning us at the following address: </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 8.5pt; text-align: center;">Ocuphire Pharma, Inc.<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">37000 Grand River Avenue, Suite 120<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Farmington Hills, MI 48335<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">(248) 957-9024<br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; text-align: center;">Attn: Dr.&#160;George Magrath, Chief Executive Officer </div></div></div><div class="BRDSX_block-frill" style="width: 468pt; margin-top: 12pt; margin-left: 0pt;"><div class="BRDSX_unknown" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 9.47pt; text-align: center;">31<br></div></div></div>
<!--End Page 54-->
<div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;"><div class="BRPFPageBreak" style="page-break-after: always;"><hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px auto; width: 612pt; height: 2px; color: #000000; background-color: #000000;"></div></div>
<!--Begin Page 55-->
<div class="BRDSX_page" style="text-align: left; margin: auto; line-height: initial; width: 456pt;"><a name="ny20058362x1_424b5_300-bcv_pg1"><!--Anchor--></a><p style="text-align: left; font-family: 'Times New Roman', Times, Serif; font-size: 8pt; font-variant: normal; font-weight: bold"><a href="#TOC">TABLE OF CONTENTS</a></p><div class="BRDSX_block-frill" style="width: 456pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div><div class="BRDSX_page-content"><div class="BRDSX_block-main" style="width: 456pt; margin-left: 0pt;"><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 174.75pt; text-align: center;"><img style="height: 96px; width: 237px;" src="logo_opusgeneticsx1.jpg"><br></div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-left: 0pt; text-align: left;">&#8201;</div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 12pt; text-align: center;">3,827,751 Shares of Common Stock<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">Pre-Funded Warrants to Purchase 7,177,033 Shares of Common Stock<br></div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 0pt; text-align: center;">7,177,033 Shares of Common Stock Issuable Upon Exercise of the Pre-Funded Warrants </div><div class="BRDSX_h1" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold; margin-top: 96pt; text-align: center;">PROSPECTUS SUPPLEMENT </div><div class="BRDSX_fpara" style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; margin-top: 300pt; text-align: center;">November&#160;5, 2025</div></div></div><div class="BRDSX_block-frill" style="width: 456pt; margin-top: 12pt; margin-left: 0pt;"><div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 1pt solid #000000; margin-top: 1pt; margin-bottom: 1pt; margin-left: auto; margin-right: auto;"> </div><div class="BRDSX_rule-full" style="height: 0pt; width: 100%; border-bottom: 2pt solid #000000; margin-bottom: 1pt; margin-left: auto; margin-right: auto; margin-top: 4pt;"> </div></div></div></div>
<!--End Page 55-->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo_ocuphire.jpg
<TEXT>
begin 644 logo_ocuphire.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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MC@N):<M&IU<;5PM7[/3$8JC53TZJZZ[._P X?#O_ (*[_MM^!Y85UGQAX?\
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M]EL][#9KXP\.VJ5L%G6.P]/6I2QN%><4I15K\]:C*MBH06MY4\33LMY63O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNH[^1#@B;(!K[YL-.T_2K2&PTNQL]-L;=!';V5A;0V=I!&HPJ0V]ND<,2*.
MJ(J@< 5G>)/%'AGP;HU[XB\7^(M"\*^'].B,VH:[XDU:PT/1[&%02TMYJ>IW
M%K96T8 )+S3HHQUK\TOB[_P69_X)Z?")KRTF^.-M\1=9LT<C1_A-H6K>./M3
MID>3;>(K2WMO!32,1M4R^*(HP>7=1S7X5[+B_C7&2K*EGO$N,<K2J0I8S,72
MOKRWA&I3P]-*UHKV=*$;648I'[;AL-DN08:-#"T<ORG#)*U.G&AA82:TYI?
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M7L\GHUH*IAL%7:O[7,JM.4:^*@I*E@J<J=%^UQ%2K]6RI555YI1M[--QA/\
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MVOOVLOB-<RW7CO\ :7^/7BR69F9EUWXM^.]0MUW')6&SGUYK2WB'18;>"*)
M J(J@ ?:/[!__!(O]J+]NT0^*?#=C9?#'X-)=&WN_BUX[MKR/3-0,3A+JW\&
M:%;A-3\7WMO\P=[=[#0XI5-O=Z[:W&(C_1Q\+_\ @VG_ &-O#6G6I^*/Q/\
MC?\ $_7EC07LNFZKX:\ >&II<#>UKHMCH&N:Y;(6SM6;Q==L!U;-?M^/XJ\(
M/#BI_9='"991QV'M"KA<IRRGC\?3:236,QKC*U9*W-#%XWZQ:S<+:GCT\-G&
M/2J2G+DEK&56I*G!^<8+6W9QA9]&S^,+2/CQ\=M N4O=!^,_Q9T2\1_,2[TC
MXC>+]-N4?.[>D]GK,,JOGG<'!SSG-?;/P7_X+!?\%&O@?>6LNA?M,^.?&NEV
M[QF;P]\7KB#XK:5>P1D'[))<^-$U3Q!8P.!L9M%US2KI5)$5Q&<$?U9>(O\
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M44 %%%% !1110 4444 %%%% !1110 4444 ?Y/'Q71O^%I?$KC_F?_&/<?\
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MF+HYC74[;N,&J/\ AA%;'CPM5S.4WJJ?-%;Z<D.33I\3;WZM]6C^G.OYZ/\
M@HYKQN?VPKO3'E,D7AWX&?#DVT<A(2VG\1^+?B7-J0A#$@-<1:#I#3E%4,(8
M 6<IA/Z%Z_F7_P""@4\L7[;'Q560;&/@;X3F 9!,EG]@\2".7J, W0O8@O\
MTQ+?Q8K\M\%:$:W'.&<K7H9=F-6%[?$Z,:+M>^O)6GMK:_F? ^,]6=/@7&0A
M>U?'9;2G9/X8XF-?7_M^C#<3]ESP>OQ.^/7PW\+20I<6*Z['X@U>+HKZ3X;
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MH892]IBJD?.GAH59KI>*(Q%54*%6L]?9P<DN[V2^;:1_&-^U?^T)XS_:N_:
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MPV%I.G1DO@KU:$G>UG\KEV&^N8QSJN4XPO6J7NE*3:Y8N]G9RUMJN6-GIO\
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M2UV^L+,,%Y*F;('.*^,]:_X*H?\ !.[0+M[*_P#VO/@U-.CE&;1O$4GB.UW
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M[\+M*F$AM;KQSXMT3PW]N:(9>+38-4O+>YU.=01_H^GPW,Y) 6,D@5\,WO\
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M "37\@?_  <QK(WQI_9@V.ZX^%_C;(5F /\ Q5=AC.TCWZU^0/\ P3%28?\
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M#^(;_@X>@\S]O/P^V['_ !CS\/1CZ>+?B/7AW_!$6WV?\%$/A&V[.-*\8?\
MIED]O2OH;_@X1A#_ +=N@,0?^3?/A^.N/^9K^(M>)?\ !$^$)_P4)^$S $8T
MKQ?U.?\ F"R>_P"%?V_ELW_Q!2"LO^2(Q*_\L*O]?Y:W^6G!+-7*^OUE/;NU
M_P -]W8_O1K\@_\ @N>F_P#X)S?%9?7Q/\-_P_XK'3>?PK]?*_(W_@N&N_\
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MLJ].E3<(1A".(KQC%:)<>;5/9TJ6%IOEA)7DEK[D6E&-VV[75W?>R^?Z/_\
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M^DC7^;E^UW-C]K']I\9Q_P 9#_&K^+_JI/B6OZ+^CQS?VGQ+R_\ 0!@+[?\
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MP9MC$TMAX=U6]\7WTA!=;>3PCI5]XITQV_N"35-$M(0YXW2",G,BAO[F:_F
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M^QQF-G]5YKIK"45'#X6Z?PMX>E3E*/23:/?PU+V-"E3ZQ@E+_$]9?BW;R/\
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MJ[U_ ;]J_P!G_/YU_?1_P1#?S/\ @GA\)F]=7\8#\M885_6WC_!K@O"-M?\
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M"-2$J<E>,E9]_)I]&G9I]&C_ "L!<$]R""058.K*P)#*RG#*RL"K*P#*P*L
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MLYI.,)6\HL[>UT^TM;"QBCM;*QMH+.SM8$$<%M:VT2PV]O#&@"QQ0Q(D<:*
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MB"V\N\@\.Z/:VOA+P3K5W:NBPHWA+P1H>A::LL,9CN?&*:CJ<$L5UIUR)_\
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M@V7B;P7XRT>\T/7]%OXQ)!=V-[$T4FTD%H;B+<);:XC*RP3HDL;!E%?PM?\
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MPO4YE!6LMFF[+777J^K^RJ_'C_@NZ_E_\$WOBPWIXI^&OZ^,M-]*_8>OQO\
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M7?BGXBNY[@M%;?V5X;\-6?@NSAU$NT;107$WB" N#&UO.IS7N7P#_P"">_\
MP4#_ ."BVJZ)\4O^"G7QD^(7AWX,17=MK>C_  "AN;7PK-XA$<@N+-KOP!X<
MMM,\+^$K9%.P:KJ^E7GBZ:W")N"RFY3UL5X7YED&%CF'&N99=PQA))NGA)5Z
M.:9YC6O^7> RW!5I4JLF_=E.OC<-1H.2E7J4XW:F&.IUI<F&C.N^LDG"E'_%
M4FE;36T8R;Z)G[K?"K]M+P/^T7\2KOP;^S9I5[\6/ OA.\EM_B1\=[9Y=+^$
M.C7$*97P[X)\036DS_$[Q1<R,@_XIF$^%+.T:6\E\53S6[:>_P!GUPOPU^&?
M@'X/>"M!^'7PR\*:-X+\%>&;-+'1?#VA6D=G8VD* ;G*H#)<75P^9;N]N7FN
M[N=GGN9I979SY)^TS^TGX9_9W\'I>3);Z]\0/$:75KX \#BX:&?6[^ 1+<ZK
MJDL22R:3X1T'[1!=>(-;EC"HLEMI.G+>>(-6T?3+[\KS_-<ERC#X_-J]997D
MF7T9UZV)S"O&4J6&I+WJV)JQA"FZM1[4J%-+FE"C2C4G:53U\NP&.S3&87+L
M#AZF,Q^,JPH8?#X>#E.K5J-*,81N[+K*4FHPBI3G*,$VO'_VX?VB9?AUX83X
M2>!M4FL_BA\1-+9KG5+%PMU\/_A_<SW%AJ_BWS<'[/KNL?9K_P />!AD2)K/
MV[Q$B7-KX4OK.X_)*P-EI=C9Z;I\$-I8:?;06=E:P*4AM[6VC6&"&-0WRI'&
MBHH]!R2>:P=5\1:YXFU_7_&'B[69?$'C#Q9J4FL>)-;G0Q&[O'18;>TLK8RR
MC3]#T:RBM](\/:0DLL6DZ-9V=DLL[QR7$U-[^**.2620)'%&\LKMG;'%$C22
M2-@DA(T5G8XX52>@K_*OQE\2<=XJ\5QK8:%>GD.6RG@>',NWJSA5J4U4QU:E
M%MO'9E.--NG%-TJ,,/A8N<J;J5/] /#/@/">'_#SI8F5*>;XU1Q>=XW:E"=.
M#<,+3J222PF!@YI3DTJE25>N^6-10A[5\-_ >J?&/QWX<^&>E-/$/$]S*NO:
MC;&19-"\&V(CE\6:X)D+-:SV^FRKI>C731R0+XJUGPY:W*B*\+#^A?3["RTJ
MPLM+TVU@L=.TVTMK"PLK6-8;:SLK.%+>UM;>% $B@MX(XX88T 5(T55   KX
MY_8O^ EQ\*/ \_C#Q78-:_$3XA6]E=:C:7,>V[\+^&+?S9]!\+2*>8=0S=3Z
MSXD4#S%UF^_LB6>\M/#^ES#[1K^\/ GPV?AOP1A\+C::CQ!G<X9KGKT<J%:=
M)1PN6\RT<<NP_P"[J).4'C*N,G3DZ=2%OY$\6>-H\:\4UJ^$FWDV5QEE^4K5
M*M2A-NOCK/9XVLN>#:4OJT,-":4X2/!OVCO@?;_M&?#6X^$&N>)-2\/> O%6
MLZ.OQ-M=%'E:KXR\!Z=<_P!HZKX BU'>ITK3/%]U:Z?I7BBY6.Y>_P#"4FNZ
M (%76GNK;V'P]X>T/PGH6C^&/#6E66A^'O#^FV>CZ)H^FP);6&F:9I\"6ME9
M6D$8"Q06\$:1QJ.<+EB6))V**_;75J.G&BYR=*$YU(4[ODC4J*$9S4=N><:=
M.,I;N,(J]HI+\OLKN5E=I)OJTFVE?LFV_FPHHHK,84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?C1_P7P8K
M_P $TOBX1_T-?PQ'Y^--,%?LO7XQ_P#!?8X_X)G_ !=_[&OX8_\ J::8?YBO
MLO#Q7X[X03Z\193_ .IE(Y<;_N>*V_@5=]O@D?Y]'FGW_P"^C_A7^HE^Q(<_
ML?\ [,I]?@A\-C^?A;3:_P MK>WK^@_PK_4B_8A.?V/?V9,_]$/^&W_J+:;7
M]&_25BHY)PS:^N:8W?\ [!(?U_6O@</7]IB;\MN2GM?^:7Z'U)117Y)7-E\;
MOC7^UM\</AMX>_:+^(/PM\/>"TT_4-,M-#,^IV2I=1QQM:PV)U?2H[6-65I-
MR22;F<C8.I_SY\1/$&? <>%J&$X9S3BS->+^(5PWE&4Y5C,HP%:IC?[+S+-Y
M5*N+SO'9?@*5&&%RO$7=7$P;FX1C=M(_8>"N#(<7O/ZN(SW <.Y=PWDKSS,L
MQS#"YEC*4,+]?P67*%/#Y5A<9C*E25?'T;*G0E:*DW9*Y^MM%?E/XC\<_M(?
ML9?$#X<K\3_BJ/CI\%OB#K\?AJ]U'6=&@TKQ-X:O)'A#W4<R37MVTUO!-]MA
MCFU74++4;>SOK5K;3+EH+NOU8J^ _$7"<;U^(LJK9'G?"G%'".,P6#XDX8X@
MCETL?E[S3"?7LJQE'&9/F&:93F.6YGA55J8/&8+'U5*5"O2K4Z-2DX//B[@K
M$<*TLES"EFV5<0Y!Q'AL5B<CS[)WC8X3&+ 8A87,,-5PV98/ 9A@L=@:\J<,
M3AL3A(.*K4ITYU(SNBBBOCS]O#QGXK\ ?LS^-/%'@KQ!JGACQ%8ZGX0BL]9T
M:ZDLM0MH[WQ5I-I=I%<1$.BW%M-+!* <-'(RG@U[O&O%&$X(X/XIXRQV&Q&,
MP7"O#^;\0XO"81TUBL3ALHP-?'UJ&'=:=.DJ]6G0E"DZLX4^>2YY1C=KR.%\
MAK\4\29#PUA:]'#8G/\ .,NR?#XC$*;H4*V8XNEA*=:LJ<95'3ISJJ<U"+DX
MI\J;L?8=%>3_  $U?5/$'P,^#&O:W?7.J:UK?PH^'>KZOJ=[*TUYJ.IZEX0T
M>\O[Z[F;+2W-W=32W$\K$M)+([L<DU\J?&3XB>.=%_;J_9M\ Z3XJUO3_!?B
M?PIK-YX@\,VM]-#H^L74$/C9H9[^S4B*XDC:QLRK."1]FA_N"O!X@\1\MX>X
M6X4XJQ&7XZOA.+<ZX&R3"8:B\.L1A:_'>9Y=EF K8ESJ1I.E@JN94JF,5*<Y
MNG3J>QC4ERI^ODW!.-SK/N(<@HXS"T:_#N5\59KB:]55G1KTN%,%C,;BZ5!0
M@YJIBH8.<,/[11BISC[1Q5VOT#HHHK]%/BPHHK\1?VB_VC_CG#\<OB3\0?AI
MXJUV#X.?LZ^,OAMX1\6^'].U&:#1M=O+C4KU-;CO[5%-I=_:]>LM1\-Z@7<N
MMHVF990R!?R?Q=\7<C\'LDRS.LZR[-<W6:9I5P-+ 9+3HUL=2P>!RK,<]SO.
M:M*M5I+^S,CR?*\9C\QJQ;E"G&G&,7.I%/\ 0_#CPXS7Q*S3'Y9EF-P&6_4,
M!#%U,9F<ZE+"3Q.*S#!95E>60J4X3_V[-<RQ^'PF#IR24YN;;2@S]NJ*S-%U
M?3_$&CZ3KVDW"7>E:WIMCJ^F749!2YT_4K6*\L[A""05FMYHY%P3PPYK3K]4
MI5:=>E3K4:D*M&M3A5I5:<E.G4IU(J<*D)Q;C*$XM2C)-J46FFTS\_J4YTJD
MZ56$J=6G.5.I3G%QG"<).,X3BTG&49)QE%I----70445^9G[8^O_ !1O/VB?
MV=?A1X!^*WBSX7Z?\1K/6+'5;_PW<3%5GCOT\F^FTY+NQCO9H8T:)%>YA(1S
M\^  ?AO$CCNCX=<,OB.KD^/SZ=3.>'LAPF4Y;6P.'Q>,S'B7.\#D.74X5\RQ
M&$P5&/US,*+JU,1B*5.%/FE*:2N?6<#\)5.-<^624\RPF40AEN<9MB<PQM+%
M5\/AL'DF68K-<9.5'!4:^*JR6&PE7DA1I3G*=HQBVTC],Z*_*7XP> ?VN?V9
M/!FH?&+PQ^U!K7Q6TKP?)97OB7P?X[\.Q""]TB>^M[*XDA>?5]9::.)[J)[J
M*VGT>]CLQ/<6>H"XB2"3]%/A%\0;?XK?#'P+\1[:S;3H_&/AK3-;DT]G\TV%
MU=0+]MLEFVH9X[2]6>WBG*(9XXTE*)OVCRN#O$[_ %CXES3@K/>$N(>!N,,K
MR?"<1?V-GM;(\PI9EP_C,76R^GFN59KPYFV<9=B:-#'T)X/&4*M;#XO#5I4N
M:A*%3G7H<3<"?V)D> XIRCB/)N+.&L?F6(R7^T\II9K@ZF"SC#8:EC)Y?F&7
M9UE^6XVA4JX2K'$8:K"E6H5J4:C]K&45&7HU%%%?J1\ %%?BE\=_CY\<OAU^
MUQX]UG0/%WB2_P#A=\)KSX?Z]XP\")J4[:,_A+74\/Z'JQCTXG[,-][K4065
MBOV6^NX+_D0.1^L7C3XH^&O"7PKUCXL-?P7'AJR\*-XIL;U&#17]I<6 O=-:
M 9!D^V++!Y:+\["3 &[BOQS@OQKX8XQQWB1E\L/CL@J^&>:9GA,WJ9P\/3HX
M[*LKQN;9;6XBRZI2K353*OK^19OA*DJBA5P];!.->$'5I\WZ;Q1X69_PUA.!
M\9&MA<WI\=X#+\1EL,M5:=7"9AF&$RW'4LEQL*E./)C_ *IF^75X*+E"M3Q*
ME2<E";7I=%?C_P#L6_%/X\>*OVC]=T7XK>,O$=_I^L^ KCQO8>$=0U.XN-,T
M2#6[R&ZTNWBLW"10R6EE*L<6Q2!"R$,2QK]@*]CPH\3<O\6>%JG%.6Y1FV1X
M>GG.:9-+ 9W3HTLPC6RNK"G.K5HT*M6-&-95(SA2J25:FGRU80FG%>;XB<!X
MWPZX@AP_CLRR_-:T\LP&9K%Y9*K/"2IX^$Y1IPJ580=1TW"474BG3GI*#:84
M45%//#:P37-Q*D-O;Q23SS2,%CBAA1I)99&/"I&BL[,> H)/2OTIM13E)J,8
MIN4FTDDE=MMZ)):MO1(^%2;:23;;222NVWHDDM6V]$EN2T5^'?AG]IWXTI\?
M?"_QGUKQ;KP_9T\:?&[Q)\+[3PW<WTRZ#8Z>MI::?9W\MC)B".&Q.KQZG!=1
M-YLMYX?U0.BJ-DO[B5^3^%7B_D'BU1XEK9+@,SRV7#F<4\OE1S6G1IU<RRS&
MX2GCLEXDP"HU:JGD^>8:56IE]2HX59?5JZG3CRIO]#\0O#;./#JKD=+-,7@<
M<LZRV>,53 2J3IX''X7$3PN:9)BG4A!K,<JKJE#&1@I4U[>DX3E=V****_63
M\["BBB@ HHHH *YGQAX+\'_$+PWJO@[Q[X5\.^-?"6N6SV>L^&?%>BZ=X@T#
M5;608>WU#2-5M[NPNXCUV3P. <, & (\-_:(^&/Q*\2VND_$+X)>,=2\,_%?
MP'#=2Z1HMSJET/!7CS2I")[WPGXFT6:9M($]XR?\2G7)+99[*Z80W-PEG(+B
MQ\7^"G[?7@'QA>S>"/C#93?!SXG:->-HVNZ3XDCFL=)CUF!EBGMI;B[Q-HDY
M=A)Y&K;;00LDL.J7,;HQ\;%<19?E6887!YCB?[+JXN<5EF+Q$U0PF,KQM+ZO
M0QC<:5/'PDN:&%JSI5ZT5[3"JLHU'3];"Y)F&88.OC,OH2Q\<)%SQU##1=7%
MX2E>RQ-7#13JRP;NE+%4XSHT9^YB)492I^T^$OVD?^#>/]B7XQ2W^M?"2X\8
M?LV^*+LRS+'X-N_^$J\ -=2DL9)_!'BFXEN;2 $XBL?#/B?PUI\"X6*T50$K
M\6/B]_P;:?MI>#I[J?X4>/?@]\9-(1W^R0G5]2^'OBFXC!^0S:3XCL;KPY;N
MPZJOC.X4'(WD<U_<;;7-M>V\%W9W$%W:7,23VUU;2QSV]Q#(H>.:":)GCEBD
M4ADDC9D=2"I((-3U^TY'XQ^(&14X4:6=SS'#024:&<4XY@DEHDL34<<<HI:*
M"Q:@EM%:,^:K9;@Z^LJ7)+^:DW3?S4?=?SB_O/\ -Y\9?\$>/^"EO@>1TU/]
ME#Q]JJ(7 F\'7_A#QS%($!)9!X1\1:S-M('R!XD9CA0I8@5YE!_P30_X*#W,
MJ01_L<_M""21@JF;X:>(+:,$_P!^:XM(H8QZM)(JCN17^FG17W5+Z2/%48)5
M\CR&K4M\=/\ M*C%O37V<L=6?R4^O32W&\BPU]*V)2[<T'^/L_T/\ZSP%_P1
M$_X*8>/9(=G[.]WX/M964->^/?&'@GPRD*MCYY;*?7I]7 4'+*FFO(.0$+ K
M7Z;? 3_@V7^*.I:CI>I?M(_'GPCX6T-)[>?4_"_PLT_4/$WB"ZMUD1[BQ7Q%
MKMKHND:9-+&'A6]BTW6DA9O-6"8($?\ L=HKP<U\?>/\QISI8:MEF3QFG'GR
M[!2E747H[5<?7QW+*UTITX4YQO>+C))K:EDV#IM.2JU6O^?E1VOZ04+KR=T?
M#'[*_P#P3?\ V/\ ]CNVMY?@W\)='B\5Q1+'<?$/Q6%\5>/;IP!ND77]3C=M
M+$C#<T&AP:7;<X\G%?<]>/\ Q8^/GPB^".GF^^)/CC1] N)+:2ZL-!$QU#Q3
MJ\48<9T?PSIZW.MZ@AD3R6N8+(V4$K*+JYMT)<?C_P#M _\ !2+QQX_AOO"W
MP:L[_P"&/A:9I+>X\67,]N_Q%U>U^XPTY[*6XTWP3#./,5KBPNM9U\PM#<V.
MK^'KU7C7^9./_%?A_AEU\PXMX@JX_-ZL>=8)XB>99YC)6O3C[*=652E"5[0K
M8NI0PT5I[5:)_HW"/A[Q-Q=5ITLDRN<<$I*-7,J\'ALLPZO:3EB)1Y:LH[NC
MAHUL0^E)J[7Z&_M/?MH>!_@);7OA?P^;'QQ\7I((Q:>$(+MAIGAG[5&LD&K^
M/=2M1)_9%I'!)'>6N@0M_P ))KZ26RV5M9:7/=>(=,_"OQ/XY\2>.O$VK^-O
M'&O77B;Q=K\HDU/6+L&-5@C>5[32-)LD9H-'\/Z6)I8M)T6SQ;6B/+,YN+ZZ
MO;VZ\I&H_/-*TCR37-Q<7EU/-(\UQ=WEW,]Q=WEW<2L\]U>7=Q))<75U<227
M%S/))-/))*[,7KJ#.P5269C@ '_(  Y).  "20!7^?WBAXJ\2>)N)CA)4Y99
MP[1KJ6"R/#595'6J*25+$YC5C&+QN+:=J<%".'P]TJ%+VDJE:K_:/A[X8Y'P
M!AY8KFCF&=U:+6,S>O"-.-&G92J4,%3ESK"X9-7J3<Y5JUKU:B@H4J?=C448
MA5)))  &XDDG  '<D\"OTZ_8A_97E\4W.D?&OXCZ<R^&;"YM-6^'>@7D?_(Q
MZA:2O+:>+-1MY5.= TZYCMKWPPK '6]1@AUV/&BV>E7&NXG[(O["VH>)6TOX
ME?'#2IK#PT-E[H7P_P!0A:*]\2J\<<MI?>);=]LVG:"I8O\ V+.D=_K<B(M^
MEIH:RVOB']G(HHH(HX((XX888TBAAB18XHHHU"1QQQH D<<: *B* JJ J@
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MITXXFM4C"4HZ.44FUHW8B%*E3NZ=.G!O1N$(QNELGRI7"OQ@M/C.WP6_;?\
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MX'#/@_Q8A3Q^5\'\.91FM25'(<YC17]L8+ T,=4GB6HJM^_<L6Y253G<W?\
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo_opusgenetics.jpg
<TEXT>
begin 644 logo_opusgenetics.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MZ^)C"-;$.A_LF%J?6'4J/,:&98R52<\=4E(HHHK]H/Y5"BBB@ HHHH ****
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M2=GTT/9:*\:_X:,_9[_Z+O\ !K_PY_@C_P"7E'_#1G[/?_1=_@U_X<_P1_\
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MJU*,*]&,:L+1JRG]8PM:#G&IAL5[:$)07*W"HH4_]3[]F_\ :%^&/[5OP/\
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M&$&S^3O]K;XU-^T=^U%^T+\>0U]]C^+?QD^(GCS1K?4G:2\T[PWXB\4ZG?\
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MW+K_ "Y?A[\:?B?_ ,$BO^"E/Q"U3X9W%]J#? #XV_$KX3>)O#5[>7>EZ?\
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M/D^H8BC04^?F]K[7!8;%\W+RKDY?K'L[<T[\G-=<W*@D $DX Y)/0#U-9?\
M;FB_]!C2_P#P86G_ ,>HUS_D"ZQ_V"]0_P#22:OQ._81_8Q_9)^+_P"S)X$\
M??%3P#8:[XWUB_\ &,.JZG/\0?'F@R3Q:7XQUS3-.5M+T/QCI&FV_DZ=:6L(
M:"PA:8()IC+-(\K[87"4*N&KXG$5J].%&MAZ*C0P\*\YRKQKS3:GB,.HQBJ#
M6CDVY+31G/C<;BJ.+PN#PF'PU>IB,/B\1*6*Q=3"4X0PM3!TW&+I8/&2G.;Q
M::3C!)0;YF[(_;:#5-,N9%AMM1L+B9LE8H+RWED8*"S%8XY&8[5!8X!P 2>
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1I623;;22;>[MU=M+O?0__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo_opusgeneticsx1.jpg
<TEXT>
begin 644 logo_opusgeneticsx1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
M     0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&
M$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W
M.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2
MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KB
MX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /[^**** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUN?AM\2/A_\ $.RA%Q=^!/&WA;QC;6S,52YF\,ZY8ZS';2,O(CN&LA#)ZH[
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M/%977J7L_9T<9.?+*,K<LXM]O1117TY^?A1110 4444 %%%% !1110 4444
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M_1XG[+'_ (D'\)?_ )KJ/^&Z/V)?^CQ/V6/_ !(/X2__ #75K]5Q7_0-B/\
MP34_^1\U]YR_VIEG_0QP'_A7A_\ Y9YK[SZGHKY8_P"&Z/V)?^CQ/V6/_$@_
MA+_\UU:.E?MH_L=:[?P:5H?[6/[-&LZI=>;]ETW2OCM\+=1O[GR(9+F?R+.S
M\537$WDV\,T\OEQMY<,4DKX1&8)X7$I7>'KI+5MT:EK=_A\T-9GELFE',,"V
MVDDL7AVVW9))*I=MMI)+>Z[GTM16-H'B/P]XKTR#6O"^O:-XDT:YS]FU;0-4
ML=8TRXP%8^1?Z=/<VLN%=&/ERMPRGHPSLUBTTVFFFM&FK-/LT]CM34DI1:E%
MI-----/9IK1I]&@HHKA/B'\4OAE\(M"B\4_%CXC>!/AAX9GU&WT>#Q%\0_%_
MA_P5H4VKW<%U<VNEQ:OXDU#3-/DU&YMK&]N+>Q2X:YF@L[J6.)H[>5D(QE.2
MC&+E*3LHQ3<F^R2NV_)$SJ0I0E4J3A3IP5Y3G)0A%+=RE)J,5YMI'=T5\L?\
M-T?L2_\ 1XG[+'_B0?PE_P#FNH_X;H_8E_Z/$_98_P#$@_A+_P#-=6_U7%?]
M V(_\$U/_D?-?><?]J99_P!#' ?^%>'_ /EGFOO/J>BOEC_ANC]B7_H\3]EC
M_P 2#^$O_P UU=;X'_:I_9@^)WB6Q\&?#7]H_P" OQ"\8:G'>2Z;X4\#_&#X
M>^+/$NH1:?:3ZA?R6.A:!XBU#5+N.QL+:YO;Q[>UD6VM+>>YF*0Q2.J>&Q,4
MY2P]>,8IMR=*HDDE=MMQLDEJV]$BH9CE]2484\?@ISG)1A"&*H2E.4FE&,8Q
MJ-RDVTDDFVVDMSWJBBN2\<>/_ GPQ\-7WC/XD^-?"7P]\'Z6]G%J?BOQQXDT
M?PGX:TZ34+R#3[".^UW7KW3]+M'OK^YMK&S2XNHVN;RX@MH0\TL:-C&,I-1B
MG*4FE&,4VVWHDDM6V]$EJSKG.%.,ISE&$(1<ISG)1C&,5>4I2;2C%)-MMI)*
M[9UM%?+'_#='[$O_ $>)^RQ_XD'\)?\ YKJ/^&Z/V)?^CQ/V6/\ Q(/X2_\
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M>6FG6=WJ%_<P6=C8VT]Y>WES(D-M:VEK$\]S<W$TA5(H((4>661V"1QJS,0
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MI2K_ - -?CQ^WY_P1-_98_X*)_%[3/CA\8/'GQX\(>.='\ :7\.K./X9>)O
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MIXOU"UU""WN[*]MO#W@?7-5>PN+.ZN+2WODO_LHLA82W5NM\TZVGG1F8,/\
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MI<P>$OB<UE&U^('CM[:8>$/$%U]HC\/7ES"[VU[9RV&I7,,^I:+!=?</@O\
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M[VZ>^U?Q#X+T^#Q'>R1I$UYXL\///X9\6W0BC5(XTN/$VC:K-'&BA$C=57@
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M/_!5^W^*W@O1OV"/C_XAT^T^)'PT\.V]G^SQXMU?4K>SE^(GP\T9([6+X7W
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ME"67Y_E,:BIQS;)<1.G+$X=2DG&GB:-2E2QF!K-6IXO#TE4YL/.O3J?RL_\
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M/]<=?PE^,_!?CCX3>-=5\'^,]&U?P=XV\):G]GO].NPUIJ&G7UK(LMM=VEU
MYCGMY0(KW2M6TZXGLK^UDMM1TV[N+6:"X?\ H._X)V?\%(!\36TCX%?M :U%
M'\1V:'3O /Q OC%;P>/MS+%:^&?$4B+'!;^-DRL.D:F5CA\7QA+.[*>+%AE\
M5_?^ 7'>3Y \3P-G6%63YEC,TJUL/CZZE2^M8Z4*6&>69@JUIX3%TG05/"1:
MA1J3<Z$H4L7*+Q?XQ],KP>XHXSC@/%SA7,)<39'E?#^'PV-R;".GB'E^41J5
M\='/\EEA5*&99?B(XN6(S*474Q5"E&EC*=3$9=":RW]IJ***_KX_S+"BBB@
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MP[JFH:=<VFGZ[!9-<6BW<VD7<T.H16K75LMP]NL1N(0_F+^=_P#PQO\ M?\
M_21CQ[_X:2R_^>558>AAZT9.MC:.$<6E&-6EBJCFFM6GAZ%5)+9J33[)HC&8
MK%8>4%A\LQ./4DW*5"O@:2IM-)1DL7BL/*3:NTX*25K-IL_2^BOP;_8_\-_M
M?_M7>"O&/C#_ (;>\>^ O^$2\>ZAX(_L[_A"K+Q3_:'V'2='U3^T_M?_  E/
MAS[)YO\ :OD?8OLMSL^S^;]K?S?+C_4;]G?X+_&/X2W'BN7XJ_M)>(/C[%KL
M.C1Z);ZWX0@\++X7DTY]3;4)K9X?$WB'[:=76\LTE5EM/LXTZ,AIO.(BZ<=E
MU+ RK4IYAAZF)HN,98>%+%J;;<;I5)X>-'2,N=WJ)-)I-RLGQ99G%?,XX>M3
MRG&4<'B8RE#%U:^7NG&*4K.5*GBYXGWIQ<$E1;3:;2C>2^GJ**^"?^"D?Q+\
M>?"?]F35/%_PX\3ZGX0\30^,O"-A%K.D21QWB6=]=W"7=NK2QRIY<Z*JR#9D
M@#!%<>%P\L7B:&&A*,9UZL*492ORQ<W9.5DW9=;)L]''XR&7X/$XVK&<Z>%H
MSK3A3MSRC3BY-1YG&-WTNTO,^]J*XWX=7]YJOP^\"ZIJ-Q)=ZAJ7@WPQ?WUU
M*09;F\O-$L;BZN)2  9)IY'D<@ %F. .E=E6,HN,I1>KC)Q;6UT['3":J0A-
M)I3C&:3W2DDTG;2]GJ%%>:?&#XL>#O@?\.?%'Q/\=WQLO#OA;3WNYDBV-?:G
M>R,L&FZ+I4,CQK<:KK%])!86$+R1Q>?.LES-;VL<]Q%^;/ARP_;B_;>L8OB"
MOQ+N?V._@=K-K:WW@'0?"=LVM_$/Q3ICNTUMXBU+5[._\,:U:V>JV\S_ &6Z
M.KZ)8W5I%87EEX0O+*>/7M3[,-@95Z<L14K4L+A(35.6)KN?*ZC2?LJ5.G&=
M6M5Y7S.-.#48^].44TWYV-S.&%K0PE'#U\=CJL'5AA,,J:E&BGRNO7JUITZ&
M'H\WN1G5J1=2?NTXS:DE^N-%?DQXH^!?[?'[.-N_CKX)?M%^(/VE=+TR0WFN
M_"CXN6<VJZWJ^EVYD M]%U/5=;U2^U&ZA@E:ZN+;0]<\':M>O9I'I\>LW4T&
MC3?ISX"U;Q7KW@SPUK/CGPK;^!_%VJ:3:7NO^$+;7(O$L7AW4+A/,DTIM<@L
MM/M]0GM59$NI;:V^RQW7G06US>P11WMPL3A(4(4ZM'%X?%4JC<4Z4I0JPE%)
MM5,/6C"M%:Z3494WMSW:0\%F%3$U:N'Q& QF Q%*$:CC7C"I0J0DVE*CB\/.
MKAYNZM*FYPJK5^S<4Y'7445^>O[8OQ[^,>A_$?X._LQ_LY3^'=)^+GQHCUK4
MKCQ?XC2*ZMO!GA;1[>\E?4;6PGM-0MGN+B+2]?OI;VZT_4_LMGX?N+2PT?4=
M1U*WGTW+"X:IBZT:--PBW&<Y5*DN6G3ITH2J5*E25G:$(1E)V3;M9)MI/;'8
MVE@,/+$5HU)I3I4J=*C'GK5JU>I&C1HTH7BI5*E2<8QO*,5?FE*,4VOT*HK\
MLS^Q?^V3H-E-XA\+?\% ?'NH^/6M[BX;2_%N@7U[X"N]0E\N:*RBLM0\2^);
M31;&*=7B:_@\*:DQMR/(T:V0O:M]-> O''[1/@G]GKQEXS_:.T+P$OQ+\&6W
MB::QA\)7\T6@ZUH^AVD<.C^)/$]Y&][;:+'JUY%=:OK,FE0B'2O#9BOWT?3=
M1%WX>T_HJX*DHQEAL=A<6Y5(TO9P5:C5YYNT6J>(I4^>FWO.+:CISJ-SEP^9
MUY3E#&97CL HT:E=5:CPV(P[ITTG*,JN%KUO9UK.ZI3C%RL^1S2;/K*BOSE_
M96_:N^(/Q7\?ZGX0\:1>&[R!;_5M$)T6.6SU:PU_2W\5WD^JP:/<6]C=:?\
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2PNWRTX1A&[W?+%)7?5VU/__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
